US20190142885A1 - Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient - Google Patents
Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient Download PDFInfo
- Publication number
- US20190142885A1 US20190142885A1 US16/078,401 US201616078401A US2019142885A1 US 20190142885 A1 US20190142885 A1 US 20190142885A1 US 201616078401 A US201616078401 A US 201616078401A US 2019142885 A1 US2019142885 A1 US 2019142885A1
- Authority
- US
- United States
- Prior art keywords
- extract
- composition
- sargassum serratifolium
- present
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000593948 Sargassum serratifolium Species 0.000 title claims abstract description 246
- 239000000203 mixture Substances 0.000 title claims abstract description 180
- 239000000284 extract Substances 0.000 title claims abstract description 146
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 87
- 239000004480 active ingredient Substances 0.000 title claims abstract description 51
- 239000003963 antioxidant agent Substances 0.000 title abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 235000013305 food Nutrition 0.000 claims abstract description 62
- 230000036541 health Effects 0.000 claims abstract description 44
- 208000030533 eye disease Diseases 0.000 claims abstract description 43
- 235000013376 functional food Nutrition 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 25
- 239000000469 ethanolic extract Substances 0.000 claims description 114
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 99
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 72
- IKUIJYZNRMQNBM-PIIINLNPSA-N (2E,6E,10E)-6,10-dimethyl-12-(5-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-2-(4-methylpent-3-enyl)dodeca-2,6,10-trienoic acid Chemical compound CC(C)=CCC\C(=C/CC\C(C)=C\CC\C(C)=C\CC1=CC(=O)C=C(C)C1=O)C(O)=O IKUIJYZNRMQNBM-PIIINLNPSA-N 0.000 claims description 69
- IKUIJYZNRMQNBM-UHFFFAOYSA-N Sargaquinoic acid Natural products CC(C)=CCCC(C(O)=O)=CCCC(C)=CCCC(C)=CCC1=CC(=O)C=C(C)C1=O IKUIJYZNRMQNBM-UHFFFAOYSA-N 0.000 claims description 68
- ASCPFLQSHKBTRD-FWXQPYBBSA-N (2z,6e,10e)-12-(2,5-dihydroxy-3-methylphenyl)-6,10-dimethyl-2-(4-methylpent-3-enyl)dodeca-2,6,10-trienoic acid Chemical compound CC(C)=CCC\C(C(O)=O)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC(O)=CC(C)=C1O ASCPFLQSHKBTRD-FWXQPYBBSA-N 0.000 claims description 66
- FNLOAPUFYUFXNF-UHFFFAOYSA-N sargahydroquinoic acid Natural products CC(=CCCC(=C/CCC(=CCCC(=CCc1cc(C)cc(C)c1O)C)C)C(=O)O)C FNLOAPUFYUFXNF-UHFFFAOYSA-N 0.000 claims description 65
- 239000002044 hexane fraction Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 59
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 230000002633 protecting effect Effects 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 150000001298 alcohols Chemical class 0.000 claims description 8
- 235000019219 chocolate Nutrition 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 235000012149 noodles Nutrition 0.000 claims description 8
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 235000015243 ice cream Nutrition 0.000 claims description 6
- 235000013372 meat Nutrition 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 235000013550 pizza Nutrition 0.000 claims description 6
- 235000011888 snacks Nutrition 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 5
- 208000033379 Chorioretinopathy Diseases 0.000 claims description 5
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 206010029113 Neovascularisation Diseases 0.000 claims description 5
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 201000005849 central retinal artery occlusion Diseases 0.000 claims description 5
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 5
- 201000010206 cystoid macular edema Diseases 0.000 claims description 5
- 208000024519 eye neoplasm Diseases 0.000 claims description 5
- 238000011010 flushing procedure Methods 0.000 claims description 5
- 201000008106 ocular cancer Diseases 0.000 claims description 5
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 5
- 230000004340 degenerative myopia Effects 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 210000004709 eyebrow Anatomy 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 239000004533 oil dispersion Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000003679 aging effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 5
- BOMUADPKDXMXIH-UHFFFAOYSA-M 1,3-bis(1-methylquinolin-1-ium-6-yl)urea;methyl sulfate Chemical compound COS([O-])(=O)=O.COS([O-])(=O)=O.C[N+]1=CC=CC2=CC(NC(=O)NC=3C=C4C=CC=[N+](C4=CC=3)C)=CC=C21 BOMUADPKDXMXIH-UHFFFAOYSA-M 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 70
- QKXAGRZCXAYBQX-WDZAAMDOSA-N (2z,6e)-9-(6-hydroxy-2,8-dimethylchromen-2-yl)-6-methyl-2-(4-methylpent-3-enyl)nona-2,6-dienoic acid Chemical compound C1=C(O)C=C2C=CC(CC/C=C(C)/CC/C=C(/CCC=C(C)C)C(O)=O)(C)OC2=C1C QKXAGRZCXAYBQX-WDZAAMDOSA-N 0.000 description 60
- QKXAGRZCXAYBQX-UHFFFAOYSA-N (2Z,6E)-9-(6-hydroxy-2,8-dimethyl-2H-chromen-2-yl)-6-methyl-2-(4-methylpent-3-enyl)nona-2,6-dienoic acid Natural products C1=C(O)C=C2C=CC(CCC=C(C)CCC=C(CCC=C(C)C)C(O)=O)(C)OC2=C1C QKXAGRZCXAYBQX-UHFFFAOYSA-N 0.000 description 59
- CWYYWDRQIIFZHK-HHHXNRCGSA-N sargachromenol Natural products CC(C)=CCCC(=CCCC(C)=CCC[C@]1(C)CCc2cc(O)cc(C)c2O1)C(O)=O CWYYWDRQIIFZHK-HHHXNRCGSA-N 0.000 description 59
- 230000036542 oxidative stress Effects 0.000 description 55
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 42
- -1 superoxide radicals Chemical class 0.000 description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 32
- 235000006708 antioxidants Nutrition 0.000 description 31
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 29
- 229940118019 malondialdehyde Drugs 0.000 description 29
- 239000000523 sample Substances 0.000 description 28
- 150000003254 radicals Chemical class 0.000 description 25
- 239000000796 flavoring agent Substances 0.000 description 24
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 235000019634 flavors Nutrition 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 238000002835 absorbance Methods 0.000 description 18
- 230000003833 cell viability Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 18
- 239000002158 endotoxin Substances 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 238000000605 extraction Methods 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000654 additive Substances 0.000 description 14
- 239000011230 binding agent Substances 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 14
- 229960005150 glycerol Drugs 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 230000002292 Radical scavenging effect Effects 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 239000007884 disintegrant Substances 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 230000002000 scavenging effect Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000000007 visual effect Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000002778 food additive Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 235000013373 food additive Nutrition 0.000 description 9
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 231100001083 no cytotoxicity Toxicity 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 241000195493 Cryptophyta Species 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 244000299461 Theobroma cacao Species 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 6
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 6
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 6
- 102000004330 Rhodopsin Human genes 0.000 description 6
- 108090000820 Rhodopsin Proteins 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000001471 micro-filtration Methods 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000195474 Sargassum Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000003674 animal food additive Substances 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000012496 blank sample Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000005445 natural material Substances 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 108091008695 photoreceptors Proteins 0.000 description 4
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 102000010175 Opsin Human genes 0.000 description 3
- 108050001704 Opsin Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000007348 radical reaction Methods 0.000 description 3
- 230000011506 response to oxidative stress Effects 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- DUUCJSJYISFGCI-WBPXWQEISA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O DUUCJSJYISFGCI-WBPXWQEISA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- ZCUQOPGIJRGJDA-UHFFFAOYSA-N 1-naphthalen-1-ylethane-1,2-diamine Chemical compound C1=CC=C2C(C(N)CN)=CC=CC2=C1 ZCUQOPGIJRGJDA-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229940079894 benzophenone-9 Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000012812 general test Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 108010048996 interstitial retinol-binding protein Proteins 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000019462 natural additive Nutrition 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000006552 photochemical reaction Methods 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 229930195724 β-lactose Natural products 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IKUIJYZNRMQNBM-FWXQPYBBSA-N CC(C)=CCC/C(=C/CC/C(C)=C/CC/C(C)=C/CC1=CC(=O)C=C(C)C1=O)C(=O)O Chemical compound CC(C)=CCC/C(=C/CC/C(C)=C/CC/C(C)=C/CC1=CC(=O)C=C(C)C1=O)C(=O)O IKUIJYZNRMQNBM-FWXQPYBBSA-N 0.000 description 1
- 0 CC(CCC=C(C)CCC=C(CCC=C(C)*)C(O)=O)(C=Cc1c2)Oc1c(C)cc2O Chemical compound CC(CCC=C(C)CCC=C(CCC=C(C)*)C(O)=O)(C=Cc1c2)Oc1c(C)cc2O 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- RPDUDBYMNGAHEM-UHFFFAOYSA-N PROXYL Chemical group CC1(C)CCC(C)(C)N1[O] RPDUDBYMNGAHEM-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 241000195475 Sargassaceae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940100609 all-trans-retinol Drugs 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 229940071128 cetostearyl sulfate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 229940080277 cholesteryl sulfate Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000089 gene mutation induction Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
Definitions
- the present invention relates to an antioxidant composition, and more particularly to an antioxidant composition including a Sargassum serratifolium extract or fraction thereof as an active ingredient, which is a useful substance (material) that can be added to medicines, cosmetics, foods, animal feeds and the like.
- the present invention also relates to a pharmaceutical composition for preventing or treating eye diseases, a food composition for alleviating eye diseases, and a health functional food, each of which includes a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- Anti-oxidation refers to the prevention of various oxidations which occur in the body. Lipids present as biological membranes and lipoproteins are attacked by free radicals in the body so as to form various kinds of peroxides. Such peroxides, decomposition products, and like are highly reactive to change the structure and function of the surrounding biomolecules, thereby resulting in the aging phenomenon and various chronic diseases.
- the body contains various antioxidant defense mechanisms which can neutralize such free radicals to protect the body.
- Human diseases and aging are caused by the oxidation of O 2 ⁇ (superoxide), NO (nitric oxide), NO 2 (nitrogen dioxide), OH (hydroxyl), ROO (proxyl), RO (alkoxyl), HO 2 ⁇ (hydroperoxyl) radical, and the like that occur during metabolism in the body.
- O 2 ⁇ superoxide
- NO nitric oxide
- NO 2 nitrogen dioxide
- OH hydroxyl
- ROO proxyl
- RO alkoxyl
- HO 2 ⁇ hydroperoxyl radical
- antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GSH-px) and antioxidants such as vitamin C, vitamin E, and glutathione remove the free radicals to protect the body against oxidative damage.
- CAT catalase
- GSH-px glutathione peroxidase
- antioxidants such as vitamin C, vitamin E, and glutathione remove the free radicals to protect the body against oxidative damage.
- ROS reactive oxygen species
- the active oxygens (O 2 ⁇ , H 2 O 2 , OH and 1 O 2 ) generated during the human physiological process are highly reactive, and the free radical reactions caused by them results in the destruction of major macromolecules including lipids (Davies, K J A and Goldberg, A L., J. Biol. Chem., 262, pp. 8220-8226, 1987). Their generation is increased by various causes that result in abnormalities in normal metabolism, photosensitization reaction, drug metabolism, and another cell metabolism. Living organisms are always exposed to the harmful effects of free radical reactions induced by them.
- ROS reactive oxygen species
- Nitric oxide synthase is converted into L-arginine L-citrulline, which produces nitric oxide.
- This nitric oxide reacts with superoxide to generate highly reactive peroxynitrite (ONOOK).
- photosensitizers such as riboflavin generate superoxide, hydroxyl radical, hydrogen peroxide (H 2 O 2 ) and the like by photochemical reaction.
- the eye tissues include antioxidant enzymes such as superoxide dismutase (SOD) including copper (Cu), zinc (Zn), and manganese (Mn), catalase, and glutathione peroxidase containing selenium (Se), lipid-soluble antioxidant compounds such as tocopherol and carotenoids, and water-soluble antioxidants such as ascorbic acid and reduced glutathione, which are involved in the removal of active oxygen.
- SOD superoxide dismutase
- Cu copper
- Zn zinc
- Mn manganese
- catalase glutathione peroxidase containing selenium
- Se lipid-soluble antioxidant compounds
- tocopherol and carotenoids lipid-soluble antioxidant compounds
- water-soluble antioxidants such as ascorbic acid and reduced glutathione
- oxidative stress which is caused by breaking the balance between the production system and the scavenging system, plays a critical role in the eye tissues and eye diseases.
- the retina of eyes is a tissue that has a high metabolic rate in the human body, causing a massive amount of oxidative stress. Further, eyes are exposed to high-energy ultraviolet rays, thereby producing a significant amount of active oxygen, which is highly reactive to result in fatal damage such as macular degeneration.
- Age-related macular degeneration (hereinafter, referred as to “AMD”) is the most active subject among studies about eye diseases. It is reported that more than 8 million people now have dry AMD, a type of this disease in the United States, and more than 3 million people are blinded by the disease each year.
- the several causes of disease include the production of reactive oxygen derivatives due to excessive oxygen use, accumulation of lipofuscin-retinoid derivatives (bisretinylethanolamine (A2E)), and oxidation by light, but the specific mechanism and treatment methods are not yet known (Zarbin, 2004, Arch Ophthalmol 122, 598-614; Kasahara et al., 2005, Invest Ophthalmol Vis Sci 46, 3426-3434).
- the light energy information received by the eye passes through the G-protein coupled receptor (GPCR) signal transferring process, thereby closing the cation channel involved in cGMP, and thus the visual cell becomes electrically polarized so that the information is transmitted to the brain in the form of electric energy.
- GPCR G-protein coupled receptor
- the retinal is changed from 11-cis structure to all-trans structure by light but is again regenerated in 11-cis structure by several proteins and enzymatic reactions.
- a series of reactions that the retinal reacts with light and are recycled by enzymes is called the visual cycle or retinoid cycle of the eye.
- the retinal reacted with light in the visual cell is hydrolyzed to be transferred to the retinal pigment epithelium so that the retinal becomes a substrate for the series of reactions.
- the recycling of retinal in the eye is a critical factor for continuous viewing of vertebrates.
- Photoreceptor cells in the retina are essential optic neurons that accept stimulation of light to convert into electrical signals.
- Rhodopsin in photoreceptor cells includes an optic and 11-cis-retinal (hereinafter, simply abbreviated as “11cRAL”).
- the 11cRAL passes through the interphotoreceptor matrix and is then transported to photoreceptor cells. Then, the 11cRAL binds to the opsin protein to form a visual purple called rhodopsin.
- Photoreceptor cells with rhodopsin are critical for sight in the dark because they may capture even tiny amounts of light.
- rhodopsin In rhodopsin, photoactivation causes the 11cRAL to be decomposed into all-trans-retinal (hereinafter, simply abbreviated as ‘atRAL’) and opsin.
- the atRAL generated herein is gradually reduced to 11cRAL by a visual cycle generated in photoreceptor cells and retinal pigment epithelium. Then, the 11cRAL binds to the opsin to re-synthesize rhodopsin (Jin M, et al., Cell, 2005).
- the atRAL and 11cRAL are intermediate metabolites of the visual cycle and are aldehyde-type compounds, which may induce excessive oxidative stress in cells so that they are strictly controlled by several enzymes in each step of the visual cycle. Mutations or dysfunctions or overexposure to the light of enzymes responsible for the visual cycle result in over-production of atRAL and accumulation of atRAL in photoreceptor cells, thereby leading to the death of photoreceptor cells.
- AtROL dehydrogenase which reduces atRAL to all-trans-retinol (hereinafter, simply abbreviated as “atROL”) and ATP-binding cassette sub-family A member 4 (Abca4) and interphotoreceptor retinoid binding protein (IRBP), which aid retinol migration between photoreceptor cells and retinal pigment epithelium, and thus photoreceptor cells in the retina is degraded
- IRBP interphotoreceptor retinoid binding protein
- 661W cells are mouse-derived photoreceptor cells, which have been widely used to study optic nerve degeneration, optic nerve protection, and the like (Tan E, et al., Investigative ophthalmology & visual science, 2004). In particular, it has been studied mainly for the response to oxidative stress such as the stimulation of ultraviolet rays and hydrogen peroxide as well as the protective effect on the optic nerve of various compounds (Kanan Y, et al., Cell Mol Neurobiol, 2015; Krishnamoorthy R R, et al., The Journal of Biological Chemistry, 1999).
- resveratrol which is abundant in the grape skin, is antioxidant to decrease the death of rat pheochromocytoma (PC12) cells induced by reactive oxygen species (M. V. Clement et al., 1998).
- the present inventors have searched for a natural substance having excellent antioxidative activity without any side effect on the living body and focused on Sargassum serratifolium .
- the present inventors examined the antioxidative effect of Sargassum serratifolium .
- the present inventors confirmed that a Sargassum serratifolium extract and fraction thereof has excellent scavenging ability of nitric oxide and intercellular reactive oxygen species, DPPH radical scavenging activity, ABTS cation scavenging activity, and hydroxyl radical (—OH) scavenging activity, thereby completing the present inventions.
- the present inventors have examined the protective effect of mouse-derived 661W photoreceptor cells using the Sargassum serratifolium extract and the compounds separated therefrom.
- the experimental group which is treated with Sargassum serratifolium extract and the compounds separated therefrom of the present invention, together with atRAL (oxidative stress inducer) shows a significant increase in cell viability compared to the experimental group treated with atRAL alone and inhibitory effect of reactive oxygen species (ROS) production and malondialdehyde (hereinafter, simply abbreviated as “MDA”) peroxide protein production, thereby completing the present invention.
- ROS reactive oxygen species
- MDA malondialdehyde
- An object of the present invention is to provide a composition that has excellent antioxidative activity and is stable to the human body over long-term use, using a natural marine algae extract.
- Another object of the present invention is to provide a food and feed additive composition that has excellent antioxidative activity and is stable to the human body over long-term use, using a natural marine algae extract.
- Still another object of the present invention is to provide a cosmetic composition that has excellent antioxidative activity and is stable to the human body over long-term use, using a natural marine algae extract.
- Yet still another object of the present invention is to provide a pharmaceutical composition that is useful for preventing or treating eye disease and is stable to the human body over long-term use, using a natural marine algae extract.
- Yet still another object of the present invention is to provide a food composition that is useful for preventing or alleviating eye disease and is stable to the human body over long-term use, using a natural marine algae extract.
- Yet still another object of the present invention is to provide a health functional food composition that is useful for preventing or alleviating eye disease and is stable to the human body over long-term use, using a natural marine algae extract.
- the present invention provides a composition having an antioxidative activity, the composition including a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- the extract may be extracted with at least one solvent selected from the group consisting of lower alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, water, and hexane.
- the lower alcohols having 1 to 4 carbon atoms may include ethanol.
- the fraction may be a hexane fraction of the Sargassum serratifolium extract.
- the composition may include a Sargassum serratifolium extract or a fraction thereof in a concentration of 0.1 ⁇ g/ml to 1000 ⁇ g/ml.
- the composition may be a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition.
- the present invention is to provide an antioxidant or anti-aging cosmetic composition including a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- the extract may be extracted with an ethanol solvent.
- the fraction may be a hexane fraction of the Sargassum serratifolium extract.
- the cosmetic composition may have one formation selected from the group consisting of a toner, a gel, soluble liquid, a milky lotion, a nutrition cream, a massage cream, an essence, an oil-in-water type emulsion, a water-in-oil type emulsion, a paste-like anhydrous product, a solid anhydrous product, an oil dispersion in aqueous phase using small spheres, an ionic lipid vesicle, a nonionic lipid vesicle, ointment, cleansing foam, cleansing water, pack, body oil, oil-in-water type makeup base, water-in-oil type makeup base, foundation, skin cover, lipstick, lip gloss, face powder, twin cake, eyeshadow, mascara, cheek color, and eyebrow pencil.
- a toner a gel, soluble liquid, a milky lotion, a nutrition cream, a massage cream, an essence, an oil-in-water type emulsion, a water-in-oil type emulsion
- the present invention is to provide a pharmaceutical composition for preventing or treating an eye disease, the pharmaceutical composition including a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- the extract may be extracted with an ethanol solvent.
- the compound may be sargahydroquinoic acid, sargaquinoic acid, or sagachromenol.
- the eye disease may be one selected from the group consisting of age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, and cystoid macular edema.
- the present invention is to provide a food composition for preventing or alleviating an eye disease, the food composition including a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- the extract may be the Sargassum serratifolium ethanol extract, and the compound may be sargahydroquinoic acid, sargaquinoic acid, or sargachromenol.
- the present invention is to provide a health functional food for preventing or alleviating an eye disease, the health functional food including a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- the extract may be the Sargassum serratifolium ethanol extract, and the compound may be sargahydroquinoic acid, sargaquinoic acid or sagachromenol.
- the food may be one selected from the group consisting of a beverage, meat, chocolate, a food, snack, pizza, ramen, another noodle, a gum, candy, ice cream, an alcoholic beverage, a vitamin complex, and a health supplement food.
- the Sargassum serratifolium extract or the compound separated therefrom may have an effect of protecting a photoreceptor cell by antioxidative activity.
- a Sargassum serratifolium extract or a fraction thereof according to the present invention has excellent DPPH radical scavenging activity, ABTS cation scavenging activity, and hydroxyl radical (—OH) scavenging activity as well as the intercellular nitric oxide and reactive oxygen species scavenging ability.
- a composition containing it as an active ingredient has an antioxidative activity, which may be useful for functional additive materials for medicines, cosmetics, foods, animal feeds, and the like.
- the Sargassum serratifolium extract or a compound derived therefrom according to the present invention has an excellent effect of protecting photoreceptor cells on the retina of the eye.
- a composition containing it as an active ingredient may be useful for medicine and health functional food materials for preventing, alleviating, or treating eye diseases.
- Sargassum serratifolium may be edible as a natural material, so that the composition of the present invention including the extract derived therefrom and fraction or compound derived therefrom has an advantage of safety over long-term use.
- FIG. 1 illustrates four fraction chromatograms obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 2 illustrates a secondary fraction chromatogram of the fraction No. 1 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 3 illustrates a chromatogram of sargahydroquinoic acid identified by NMR analysis on a product obtained by purifying a secondary fraction of the fraction No. 1 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 4 illustrates the results of confirming three peaks in the secondary fraction chromatogram of the fraction No. 2 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 5 illustrates a chromatogram of sagachromenol identified by NMR analysis on a product obtained by purifying 2nd peak of the secondary fraction of the fraction No. 2 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 6 illustrates the results of confirming four peaks in the secondary fraction chromatogram of the fraction No. 3 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 7 illustrates a chromatogram of sargaquinoic acid identified by NMR analysis on a product obtained by purifying 4th peak of the secondary fraction of the fraction No. 2 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction.
- FIG. 8 illustrates the results of measuring the cytotoxicity of macrophage (RAW 264.7) according to treatment concentration of a Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention.
- FIG. 9 illustrates the results of measuring LPS-induced nitric oxide production in macrophages according to treatment concentration of a Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention.
- FIG. 10 illustrates the results of measuring LPS-induced reactive oxygen species (ROS) in macrophages according to treatment concentration of a Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention.
- ROS reactive oxygen species
- FIG. 11 illustrates the results of measuring the cytotoxicity of 661W, photoreceptor cells according to treatment with a Sargassum serratifolium ethanol extract (hereinafter, simply abbreviated as “SSE”) of the present invention.
- SSE Sargassum serratifolium ethanol extract
- FIG. 12 illustrates the results of measuring the cytotoxicity of 661W, photoreceptor cells according to treatment with a compound selected from SSE ((sargahydroquinoic acid (hereinafter, simply abbreviated as “SHQ”), sargaquinoic acid (hereinafter, simply abbreviated as “SQA”) or sargachromenol (hereinafter simply abbreviated as “SCM”)).
- SSE sargahydroquinoic acid
- SQA sargaquinoic acid
- SCM sargachromenol
- FIG. 13 illustrates the results of measuring cell viability of 661W cells according to the combined treatment of 661W photoreceptor cells derived from mice with an atRAL compound as oxidative stress inducer, a Sargassum serratifolium ethanol extract (SSE) and compounds separated therefrom of the present invention (SHQ, SCM, SQA), respectively.
- SSE Sargassum serratifolium ethanol extract
- SHQ, SCM, SQA compounds separated therefrom of the present invention
- FIG. 14 illustrates the results of measuring the inhibitory level of reactive oxygen species production according to the combined treatment of 661W photoreceptor cells derived from mice with an atRAL compound as oxidative stress inducer, a Sargassum serratifolium ethanol extract (SSE) and compounds separated therefrom of the present invention (SHQ, SCM, SQA), respectively.
- SSE Sargassum serratifolium ethanol extract
- FIG. 15 illustrates the results of the protein immunoassay on an amount of malondialdehyde (MDA) protein in cells according to the combined treatment of 661W photoreceptor cells derived from mice with an atRAL compound as oxidative stress inducer, a Sargassum serratifolium ethanol extract (SSE) and compounds separated therefrom of the present invention (SHQ, SCM, SQA), respectively.
- MDA malondialdehyde
- RAW 264.7 cells (5 ⁇ 10 4 cells/well) were treated with the Sargassum serratifolium ethanol extract or hexane fraction thereof, respectively, of the present invention prepared in Example 1, and cultured in DMEM medium for 24 hours. 95 ⁇ l the medium and 5 ⁇ l the MTS solution were placed in a 96-well plate and were reacted for 3 hours. Then, the absorbance thereof was measured at 490 nm using a microplate reader. The experiments were repeated three times, and the mean value thereof was used as its measurement value.
- the results indicate that the cytotoxicity of Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention to the macrophage line (RAW 264.7 cells) did not show up to a concentration of 8 ⁇ g/mL.
- Nitric oxide, reactive oxygen species (ROS), antioxidative activity by DPPH method, ABTs antioxidative activity, and hydroxyl radical were measured so as to evaluate the antioxidative activity of Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention prepared in Example 1.
- RAW 264.7 cells (7 ⁇ 10 4 cells/well) were inoculated into 96-well plates using DMEM medium.
- New medium containing samples Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1
- LPS (1 ⁇ g/mL) were co-treated and were cultured for 24 hours.
- the Griess reagent was used, so that the amount of NO produced was measured in the form of NO 2 ⁇ present in the cell culture medium.
- 100 ⁇ L the cell culture supernatant and 100 ⁇ L Griess reagent [1% sulfanilamide, 0.1% naphthyl ethylenediamine in 5% phosphoric acid] were mixed and reacted on a 96-well plate for 10 minutes. Then, the absorbance thereof was measured at 540 nm using an ELISA reader. Standard concentration curves were obtained by serial dilution of sodium nitrite (NaNO 2 ).
- the results indicate that the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with a Sargassum serratifolium ethanol extract and a hexane fraction thereof in macrophages, respectively.
- the EC 50 values of the ethanol extract and hexane fraction were 1.72 ⁇ g/mL and 1.51 ⁇ g/mL, respectively.
- DCFH-DA was used to measure the amount of active oxygen so as to examine the inhibitory effect of the Sargassum serratifolium extract on the production of reactive oxygen species (RAW 264.7 cells).
- Samples Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1 and LPS (1 ⁇ g/mL) were co-treated and were cultured for 2 hours. Then, they were treated with 20 ⁇ M DCFH-DA and were cultured for 30 minutes. Thereafter, the cell culture supernatant was collected and measured by spectrofluorometry at an excitation wavelength of 485 nm and a radiation wavelength of 523 nm.
- the results indicate that the production of reactive oxygen species induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with a Sargassum serratifolium ethanol extract and a hexane fraction thereof in macrophages, respectively.
- the IC 50 values of the ethanol extract and hexane fraction were 0.92 ⁇ 0.09 ⁇ g/mL and 0.88 ⁇ 0.08 ⁇ g/mL, respectively.
- the DPPH method (Blois, M. S.: Antioxidant determination by the use of a stable free radical, Nature, 26, 1199-1200, 1958) was used to measure the antioxidant effect of Sargassum serratifolium in vitro.
- the DPPH (1,1-diphenyl picrylhydrazyl) method is a method of measuring the antioxidative effect by hydrogen donating ability according to the degree of discoloration of deep purple color by reduction due to a physiologically active substance having an antioxidative activity such as tocopherol, ascorbate, flavonoid compounds, aromatic amines, Maillard-type browning agent, and peptide.
- 100 ⁇ l DPPH having a concentration of 200 ⁇ M and 100 ⁇ l the sample were mixed in a 96-well plate, and they reacted at room temperature for about 30 minutes. Then, the absorbance thereof was measured at 517 nm using a microplate reader. BHT was used as a positive control. The concentration was compared at the same as that of the sample.
- DPPH radical scavenging activity was calculated by the method as described below.
- Radical scavenging activity(%) ( A DPPH ⁇ A sample )/ A DPPH ⁇ 100
- the ABTs assay is similar to the DPPH assay but differs in that antioxidative activity is measured by generating free radicals through chemical reactions. ABTs are reacted with potassium persulfate to generate ABTs anion radicals, which react with H-donors such as phenolic compounds to be converted to colorless ABTs. Accordingly, the degree of antioxidative activity may be determined by measuring the amount of ABTs consumed by reacting with a sample containing a phenolic compound.
- ABTs antioxidative activity was measured by partially modified Van den Berg (1999) and others using the discoloration of ABTs radical-specific green color by antioxidants.
- Potassium persulfate was added to 7 mM ABTs solution at a final concentration of 2.4 mM. They reacted in the dark for 12 hours to 16 hours at R/T so as to produce ABTs cations.
- the resulting ABTs cation was diluted to be used, having an absorbance value of 0.7 ⁇ 0.02. 10 ⁇ L the sample was treated with 190 ⁇ L ABTs+ working solution and reacted for 6 minutes in a 96-well plate. The absorbance thereof was measured at 732 nm.
- the radical scavenging activity was calculated from the measured values as follows. BHT was used as a positive control. The antioxidant ability of the sample is determined by the IC 50 value in which 50% of ABTs was reduced.
- Percentage inhibiting activity I (%) ( A control A sample )/ A control / ⁇ 100
- Control (blank sample)
- a control Sample measurement value
- Hydroxyl radicals are the most reactive radicals among oxygen radicals, which occur during aerobic metabolism in the human body. These radicals damage peripheral cells to create collateral living body molecules.
- a deoxyribose test was performed so as to measure the ability to scavenge hydroxyl radicals. Hydroxyl radicals attack deoxyribose to create small fragments. Some of which are pink when added with TBA (thiobarbituric acid) under an acidic pH environment, so the degree of damage by hydroxyl radicals is measured by absorbance at 532 nm.
- TBA thiobarbituric acid
- Fe2+-EDTA mixture which is an oxidized form of ferric chloride (FeCl 3 ) and ethylenediamine tetraacetic acid (EDTA).
- EDTA ethylenediamine tetraacetic acid
- 0.5 ml of 20 mM hydrogen peroxide (H 2 O 2 ) was added to form Fe3+-EDTA and HO radical. They were then incubated at 37° C. for 1 hour. After the incubation, 1 ml of 2.8% Trichloroacetic acid (TCA) and 1% TBA, respectively, were added. The mixture was boiled in boiling water at 100° C. for 30 minutes. The absorbance thereof was measured.
- BHT (2 ⁇ g/ml to 25 ⁇ g/ml) was used as a positive control.
- Hydroxy radical scavenging ability(%) ( A control ⁇ A sample )/ A control ⁇ 100
- Control (blank sample)
- a control Sample measurement value
- 661W photoreceptor cells were cultured in 96-wells at a concentration of 3 ⁇ 10 3 cells/well. Then, they were treated with 1.0 ⁇ g/ml Sargassum serratifolium ethanol extract or compounds separated therefrom (sargahydroquinoic acid (SHQ), sargachromenol (SCM), and sargaquinoic acid (SQA)) at a concentration of 1.0 ⁇ M and cultured for 24 hours. Then, the medium was replaced with medium containing MTS reagent. Then, they were cultured for 1 hour. Cell viability was measured by measuring the absorbance at 490 nm and comparing the results. The cell viability thereof was analyzed by Celltiter 96 Aqueous One solution assay kit (Promega).
- the results indicate that no cytotoxicity was observed in the 661W photoreceptor cells in both Sargassum serratifolium ethanol extract (1 ⁇ g/ml) and the compound separated therefrom (1 ⁇ M).
- the atRAL is an intermediate metabolite of the visual cycle and is an aldehyde-type compound.
- the atRAL may induce excessive oxidative stress in cells. Therefore, when 661W photoreceptor cells were treated with the atRAL compound to induce the oxidative stress, the protective effect of the Sargassum serratifolium ethanol extract and the compound separated therefrom of the present invention on 661W photoreceptor cells was examined.
- 661W photoreceptor cells were cultured in 96-wells at a concentration of 3 ⁇ 10 3 cells/well and treated with atRAL having a concentration of 1.8 ⁇ M (Sigma Aldrich, St. Louis, Mo., USA) for 24 hours. Then, the medium was replaced with medium containing MTS reagent, and they were cultured for 1 hour. The absorbance thereof was measured at 490 nm, and the results were compared to determine cell viability. The cell viability thereof was measured by Celltiter 96 Aqueous One solution assay kit (Promega).
- the results indicate that the cell viability of 661W photoreceptor cells was reduced by about 55% in the only atRAL-treated group, whereas the cell viability in the experimental group treated with 0.5 ⁇ g/mL Sargassum serratifolium ethanol extract and atRAL was increased by about 25% compared to the experimental group treated with the only atRAL.
- the cell viability of 661W photoreceptor cells was more than 90% in the experimental group treated with 0.5 ⁇ M of sargahydroquinoic acid (SHQ), sargachromenol (SCM) and sargaquinoic acid (SQA), respectively, so that no significant difference was found between the atRAL-treated group and the untreated group.
- SHQ sargahydroquinoic acid
- SCM sargachromenol
- SQA sargaquinoic acid
- DCFH-DA 2′,7′-dichlorodihydrofluorescein diacetate
- the results demonstrate that the cells treated with atRAL only had a fluorescence expression level having about 80% higher than that of the control group.
- the fluorescence expression level was reduced by about 75% compared to the group treated with atRAL only.
- the fluorescence expression levels were reduced by 76%, 77%, and 73%, respectively, and there was no difference from the control group untreated with atRAL.
- the Sargassum serratifolium ethanol extract and the compound separated therefrom were found to effectively inhibit atRAL-induced oxidative stress, thereby protecting photoreceptors.
- samples of each of Sargassum serratifolium ethanol extract and the compounds separated therefrom were mixed with a specific amount of atRAL (1.8 ⁇ M) and Sargassum serratifolium ethanol extract (0.5 ⁇ g/mL), sargachromenol (0.5 ⁇ M), sargahydroquinoic acid (0.5 ⁇ M), or sargaquinoic acid (1.0 ⁇ M).
- the photoreceptor cells were treated with mixtures thereof. Then, they were cultured for 2 hours. The cells were then washed with PBS and the intracellular proteins were recovered. The number of proteins denatured by the lipid peroxides in cells was analyzed by protein immunoassay using MDA immunoblot kit (Cell biolabs).
- the results indicate that the cells treated with atRAL only showed an increase in expression level of protein denatured by MDA compared with the control, whereas the group treated with atRAL and Sargassum serratifolium ethanol extract having 0.5 ⁇ g/mL of the present invention has decreased expression level of MDA peroxidase protein compared with the group treated with atRAL only.
- the expression level of MDA peroxidase protein was similarly decreased in the experimental groups treated with atRAL and the compounds separated from Sargassum serratifolium ethanol extract, respectively.
- the Sargassum serratifolium ethanol extract and the compound separated therefrom effectively inhibit atRAL-induced oxidative stress so that the photoreceptors are protected by inhibiting peroxidation of cell membrane lipid component.
- the present invention is characterized by providing an antioxidant composition including a Sargassum serratifolium extract or a fraction thereof in an active ingredient.
- Sargassum serratifolium of the present invention is a marine algae in Sargassaceae family of phaeophyta division, which is distributed in the south coast and Jeju region in Korea.
- the plant is 1 m to 4 m and its root diameter is 4 cm to 5 cm, which has cone-shape. It is like rubber and has a ring.
- the present inventors have selected the Sargassum belonging to Sargassum family as a substance of medicines, food, and cosmetic composition and produced extracts thereof. It is confirmed that Sargassum serratifolium among various kinds of Sargassum has an excellent antioxidative activity.
- the present inventor measured the amount of nitric oxide produced in the following Experimental Example ⁇ 2-1>.
- the results indicate that the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently.
- the EC 50 values of the ethanol extract and the hexane fraction were 0.72 ⁇ g/mL and 0.68 ⁇ g/mL, respectively (See FIG. 9 ).
- DPPH radical scavenging activity was measured in the following Experimental Examples ⁇ 2-3> to ⁇ 2-5>, respectively.
- the results demonstrate that the Sargassum serratifolium ethanol extract and the hexane fraction thereof of the present invention showed 50% scavenging activity (IC 50 ) in the concentration range of 1 ⁇ g/ml to 20 ⁇ g/ml. These values show a higher antioxidative activity compared with BHT as a positive control group (See Table 1).
- composition of the present invention including Sargassum serratifolium extract and fraction thereof as an active ingredient may be useful as a functional material showing an antioxidative activity.
- the Sargassum serratifolium extract according to the present invention may be used as one obtained by extracting and separating from nature using an extraction and separation method known in the art.
- the “extract” defined in the present invention may be extracted from Sargassum serratifolium using an appropriate solvent. It includes, for example, a crude extract, polar solvent extract or non-polar solvent extract of Sargassum serratifolium
- Any pharmaceutically acceptable organic solvent may be used as an appropriate solvent for extracting the extract from the Sargassum serratifolium .
- Water or an organic solvent may be used.
- Various solvents such as purified water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, and butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination, but the solvent may not be limited thereto.
- ethanol may be used, and more preferably, 95% ethanol may be used.
- the extraction method may use any one selected from methods including hot water extraction, chilling extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, pressing, and the like. Further, the desired extract may additionally perform a general fraction process and be purified using a general purification method.
- the method of preparing the Sargassum serratifolium extract of the present invention is not limited and may use any known method.
- a primary extract extracted by the hot water extraction or solvent extraction may be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying, or spray-drying. Further, the primary extract may obtain additionally purified fractions using various types of chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, and the like.
- the Sargassum serratifolium extract is a concept including all of the extracts, fractioned and purified materials, their dilutions, concentrates, or dried materials which are obtained in each step of extraction, fraction, or purification.
- the dried Sargassum serratifolium is powdered. Then, 95% ethanol is used as an extraction solvent to perform the extraction using the reflux cooling extraction, followed by filtration and concentration.
- This Sargassum serratifolium ethanol extract can be further fractionated using an n-hexane solvent.
- the Sargassum serratifolium ethanol extract is dissolved in a mixed solvent of water and ethanol in a volume ratio of 9:1, and then equilibrated by adding the same amount of n-hexane. Then, the upper n-hexane soluble portion may be filtered and concentrated to produce the hexane fraction of Sargassum serratifolium ethanol extract.
- composition of the present invention corresponds to an antioxidant composition including the Sargassum serratifolium extract or the fraction thereof as an active ingredient.
- antioxidant composition refers to a substance that prevents oxidation by inhibiting or eliminating active oxygen having an unstable state of oxygen.
- the antioxidant composition of the present invention may be used for various objects and purposes requiring antioxidative activity.
- the antioxidant composition may be used as a functional material which provides the antioxidative activity products which are applicable to various industrial fields such as pharmaceuticals, cosmetics, foods, and animal feed. It can also be used as a substance such as medicine preservative, a cosmetic preservative, a food preservative, a pharmaceutical additive, a cosmetic additive, a food additive, and a feed additive.
- the antioxidant composition of the present invention may be a pharmaceutical composition for preventing or treating oxidation-related diseases, including a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- the pharmaceutical composition of the present invention may be prepared by using pharmaceutically-suitable and physiologically-acceptable additives in addition to the active ingredient, and the additives may be an excipient, a disintegrant, a sweetener, a binder, a coating agent, an inflating agent, a glidant, a lubricant, a flavoring agent, and the like.
- the pharmaceutical composition may preferably be formulated as a pharmaceutical composition by additionally including at least one of pharmaceutically acceptable carriers in addition to the active ingredient for administration.
- a formulation of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppository, liquid, syrup, juice, a suspension, an emulsion, an ointment, an injectable liquid formulation, and the like.
- an active ingredient may be combined with an oral and non-toxic pharmaceutical acceptable inert carrier, such as ethanol, glycerol, water in order to formulate as a type of tablets or capsules.
- a suitable binding agent, a lubricant, a disintegrant and a coloring agent may be also included as a mixture.
- the suitable binding agent includes starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweetening agents, natural or synthetic gums such as acacia, tragacanth, or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like, but is not limited thereto.
- the disintegrant includes starch, methylcellulose, agar, bentonite, xanthan gum, and the like, but is not limited thereto.
- a pharmaceutically acceptable carrier for a composition formulated as a liquid solution may be suitable for a sterilization and a body, and may be saline solution, sterilized water, Ringer solution, butter saline solution, albumin injection solution, dextrose solution, malto dextrin solution, glycerol, ethanol, and the mixture of at least one thereof, and other general additives, such as antioxidants, a buffering solution, and bacteriostat may be added as needed.
- tablets, granules, capsules, a pill, a dosage form for injecting such as an aqueous solution, suspension, and an emulsion may be formulated by additionally adding a diluent, a dispersing agent, a surfactant, a binding agent, and a lubricant.
- a diluent such as an aqueous solution, suspension, and an emulsion
- a dispersing agent such as a a surfactant, a binding agent, and a lubricant.
- the Sargassum serratifolium extract or fraction thereof of the present invention may be included in 0.00001% by weight to 40% by weight with respect to the total weight of the composition.
- the Sargassum serratifolium extract or fraction thereof of the present invention may be included at a concentration of 0.1 ⁇ g/ml to 10000 ⁇ g/ml with respect to the composition.
- the oxidation-related diseases in which the pharmaceutical composition of the present invention may have a therapeutic effect may include nasitis, asthma, acute pain, chronic pain, paradentitis, gingivitis, inflammatory bowel disease, gout, myocardial infarction, arteriosclerosis, congestive heart failure, hypertension, angina pectoris, stomach ulcer, Alzheimer's disease, cerebral infarction, Down's syndrome, multiple sclerosis, obesity, diabetes, dementia, depression, schizophrenia, tuberculosis, sleep disorder, sepsis, a burn, pancreatitis, and eye diseases, but is not limited thereto.
- composition of the present invention may also be a food composition.
- a food composition may include various flavors or natural carbohydrates as well as the Sargassum serratifolium extract or fraction thereof as an active ingredient like conventional food compositions.
- natural carbohydrates examples include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as general sugar including dextrin and cyclodextrin and sugar alcohols such as xylitol, sorbitol and erythritol.
- Natural flavors thaumatin
- stevia extract e.g., rebaudioside A, glycyrrhizin, etc.
- synthetic flavors e.g., saccharin, aspartame, etc.
- the food composition of the present invention may be formulated in the same method as the pharmaceutical composition. So, the food composition may be used as a functional food or in by adding to various foods. Examples of foods to which the composition of the present invention may be added include beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- the food composition may include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like as well as the Sargassum serratifolium extract and fraction thereof as an active ingredient.
- the food composition of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks, and vegetable drinks.
- Such a Sargassum serratifolium extract or a fraction thereof, which is the active ingredient of the present invention, is a natural material and has few side effects, unlike chemicals, so that it can be safely used for long-term use for the purpose of imparting antioxidant function.
- the present invention may include a health functional food for preventing or alleviating oxidation-related diseases, in which the health functional food may include a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- the health functional food of the present invention may be produced and processed in the form of tablets, capsules, powders, granules, liquids, and pills for the purpose of preventing or alleviating oxidation-related diseases.
- health functional food in the present invention refers to foods produced or processed using raw materials or components that have useful functionality in the human body according to the health functional food law or means that the food is ingested for the purpose of obtaining a beneficial effect for health use such as controlling nutrients or physiological action for the structure and function of the human body.
- the health functional food of the present invention may include common food additives.
- the conformity of the “food additive” is determined, as long as there are no other regulations, in consideration with the standard and criteria of the corresponding item according to the general rule of the food additives codex and general tests approved by the Korean Ministry of Food and Drug Safety.
- the items listed on the “food additives codex” include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon color, licorice extract, crystalline cellulose, kaoliang color, and guar gum; and mixed preparations such as L-glutamic acid sodium preparations, alkalis additives for noodle, preservative preparations, tar color preparations.
- a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention, excipients, binders, disintegrants, and other additives can be granulated using a conventional method, and then compression molding process is performed with lubricants.
- the mixture can be directly subjected to the compression molding process.
- the health functional food in a tablet form may include sweetening agents.
- a hard capsule formulation can be produced by filling a conventional hard capsule with a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention and additives such as excipients; and a soft capsule formulation can be produced by filling a capsule support of gelatin with a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention and additives such as excipients.
- the soft capsule formulation can include plasticizers, such as glycerin or sorbitol, coloring agents, and preservatives.
- a health functional food in a pill form can be produced by molding a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods.
- the health functional food in a pill form can be coated with white sugar or other coating materials, or the surface thereof can be coated with starch, talc, or other materials.
- a health functional food in a granule form can be produced by granulating a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods.
- the health functional food in a granule form can include flavoring agents and sweetening agents.
- the health functional food containing the Sargassum serratifolium extract or the fraction thereof as an active ingredient of the present invention has been experimentally proved to have excellent antioxidative effects as shown in the following examples, and thus it is effective for preventing or alleviating oxidation-related diseases.
- the health functional food may be beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- composition of the present invention may be a cosmetic composition as well as a pharmaceutical composition or a food composition.
- the Sargassum serratifolium extract or fraction thereof of the present invention has an excellent scavenging activity against the most reactive hydroxyl radicals among the reactive oxygen species as well as scavenging activity against nitric oxide so that it has an excellent antioxidative activity.
- the composition including the Sargassum serratifolium extract or fraction thereof may be useful as a cosmetic composition because it is effective for skin protection and skin treatment from reactive oxygen species (ROS) that induce damage to human cells to accelerate aging and mediate oxidation-related diseases.
- ROS reactive oxygen species
- the composition of the present invention may include not only the Sargassum serratifolium extract or fraction thereof, but also compositions commonly used in cosmetic compositions such as commonly used supplements such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.
- composition of the present invention may be used in combination with the above-mentioned Sargassum serratifolium extract or fraction thereof and conventionally used antioxidants to the extent that it does not adversely affect the skin protecting effect by reacting with the Sargassum serratifolium extract or fraction thereof.
- Examples of products added to the cosmetic composition of the present invention may include cosmetics such as astringents, toners, nutritional lotions, various creams, essences, packs and foundations, cleansers, facial cleaning agents, soaps, treatment agents, and beauty liquids.
- cosmetics such as astringents, toners, nutritional lotions, various creams, essences, packs and foundations, cleansers, facial cleaning agents, soaps, treatment agents, and beauty liquids.
- compositions of the present invention include skin lotions, skin softeners, skin toners, astringents, lotions, milky lotions, moisturizing lotions, nutritional lotions, massage creams, nutritional creams, moisturizing creams, hand creams, essences, nutritional essences, packs, soap, shampoo, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, milky liquid, lipsticks, makeup base, foundations, press powders, loose powders, eyeshadow, and the like.
- the content of the Sargassum serratifolium extract or fraction thereof of the present invention is 0.00001% by weight to 40% by weight, preferably 0.1% by weight to 20% by weight, more preferably 1.0% by weight to 20% by weight with respect to the total weight of the composition.
- the content of the Sargassum serratifolium extract or fraction thereof is less than 0.00001% by weight, the antioxidative effect caused by the extract and the fraction thereof is significantly reduced.
- the content is more than 40% by weight, skin irritation may be caused and a problem may occur in the formulation thereof.
- the cosmetic composition according to the present invention can be formulated in which the Sargassum serratifolium extract or fraction thereof is contained inside the nanoliposome, resulting in its stabilization.
- the composition of the extract (or fraction thereof) is stabilized.
- problems such as precipitation formation, discoloration, and changing scent may be solved.
- the solubility and transdermal absorption rate thereof may be improved. Therefore, the expected efficacy from the extract (or fraction thereof) may be maximized.
- nanoliposomes are liposomes having a typical liposome shape and refer to liposome having an average particle diameter of 10 nm to 500 nm.
- the average particle diameter of the nanoliposome is 50 nm to 300 nm.
- the average particle diameter of the nanoliposome exceeds 300 nm, among technological effects to be achieved in the present invention, the improvement of the skin penetration thereof and the improvement of the formulation stability thereof are very weak.
- the nanoliposomes used to stabilize the extract (or fraction thereof) according to the present invention may be prepared using a mixture including a polyol, an oily composition, a surfactant, a phospholipid, a fatty acid, and water.
- the polyol used in the nanoliposome of the present invention is not particularly limited, but preferably includes at least one selected from the group consisting of propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isopropylene glycol, pentylene glycol, erythritol, xylitol, sorbitol, and mixtures thereof.
- the content thereof is 10% by weight to 80% by weight, preferably 30% by weight to 70% by weight, with respect to the total weight of the nanoliposome.
- the oil composition used in the preparation of the nanoliposome of the present invention may include a variety of oils known in the art and, but include preferably hydrocarbon-based oil such as hexadecane and paraffin oil, an ester-based synthetic oil, silicone oil such as dimethicone-based oil and cyclomethicone-based oil, animal-vegetable oil such as sunflower oil, corn oil, soybean oil, avocado oil, sesame oil and fish oil, ethoxylated alkyl ether-based oil, propoxylated alkyl ether-based oil, sphingoid lipid such as phytosphingosine, sphingosine and sphinganine, cerebroside cholesterol, sitosterol cholesteryl sulfate, cetostearyl sulfate, C 10-40 fatty alcohols and mixtures thereof.
- the amount thereof may be 1.0% by weight to 30.0% by weight, and preferably 3.0% by weight to 20.0% by weight with respect to the total weight of the nanolipo
- any surfactant known in the art may be used as the surfactant used in the preparation of the nanoliposome of the present invention.
- anionic surfactants cationic surfactants, amphoteric surfactants and nonionic surfactants may be used.
- anionic surfactants and nonionic surfactants may be used.
- Specific examples of anionic surfactants include alkyl acyl glutamate, alkyl phosphates, alkyl lactylate, dialkyl phosphate and trialkyl phosphate.
- Specific examples of nonionic surfactants include alkoxylated alkyl ether, alkoxylated alkyl ester, alkyl polyglycoside, polyglyceryl ester and sugar ester.
- the preferred surfactant is polysorbate-based compound belonging to nonionic surfactants. The amount thereof may be 0.1% by weight to 10% by weight, preferably 0.5% by weight to 5.0% by weight with respect to the total weight of the nanoliposome.
- the phospholipids include natural phospholipids (for example, egg yolk lecithin or soy lecithin, sphingomyelin) and synthetic phospholipids (for example, dipalmitoyl phosphatidylcholine or hydrogenated lecithin).
- the phospholipid is lecithin.
- unsaturated lecithin or saturated lecithin derived from natural origin extracted from soybean or egg yolk is preferred.
- the amount of phosphatidylcholine in the naturally occurring lecithin is 23% to 95%, and the amount of phosphatidyl ethanolamine is 20% or less.
- the amount of phospholipid to be used is 0.5% by weight to 20.0% by weight, preferably 2.0% by weight to 8.0% by weight with respect to the total weight of the nanoliposome.
- the fatty acid used in the preparation of the nanoliposome of the present invention includes higher fatty acids, preferably saturated or unsaturated fatty acids of C 12-22 alkyl chains, such as lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid.
- the amount thereof may be 0.05% by weight to 3.0% by weight, preferably 0.1% by weight to 1.0% by weight with respect to the total weight of the nanoliposome.
- the water used in the preparation of the nanoliposome of the present invention is generally deionized distilled water.
- the amount thereof may be 5.0% by weight to 40% by weight with respect to the total weight of the nanoliposome.
- the nanoliposome may be prepared by a variety of methods known in the art, but the most preferred method is carried out by applying a mixture including the components to a high-pressure homogenizer.
- the nanoliposome may be prepared by a high-pressure homogenizer under various conditions (for example, pressure, number of times, etc.) depending on the desired particle size.
- the nanoliposome may be prepared in which the mixture passes through a high-pressure homogenizer 1 to 5 times at a pressure of 600 bar to 1200 bar.
- the cosmetic composition according to the present invention may contain the Sargassum serratifolium extract or fraction thereof having 0.1% by weight to 20.0% by weight with respect to the weight of the nanoliposome and more preferably 1.0% by weight to 10.0% by weight for stabilizing the formulation.
- the Sargassum serratifolium extract or fraction thereof may be included in the cosmetic composition at a concentration of 0.1 ⁇ g/ml to 10000 ⁇ g/ml.
- composition of the present invention may be a feed composition or a feed additive which may impart the antioxidant functionality thereto.
- the feed composition according to the present invention may contain the Sargassum serratifolium extract or fraction thereof in an amount of 0.1% by weight to 50% by weight, more preferably 1% by weight to 20% by weight with respect to the total weight of the composition, but is not limited thereto. Meanwhile, when used as a feed additive, the Sargassum serratifolium extract or fraction thereof can be mixed and used in the feed composition.
- the present invention provides an antioxidation or anti-aging method including administering a Sargassum serratifolium extract or a compound separated therefrom to an individual.
- the antioxidation or anti-aging method of the present invention includes administering a Sargassum serratifolium extract or a compound separated therefrom of the present invention to an individual in a therapeutically effective amount.
- the specific therapeutically effective amount for any particular individual may vary depending on various factors well known in the medical art and other factors including the kind and degree of the response to be achieved, whether other agents are used therewith or not, specific composition, the patient's age, body weight, health conditions, gender, and diet, the time and route of administration, the secretion rate of the composition, the time period of therapy, other drugs used in combination or coincidentally with the specific composition. Therefore, the effective amount of the composition suitable for the purpose of the present invention is preferably determined in consideration of the matters as described above.
- the mammal includes livestock such as cows, pigs, sheep, horses, dogs and cats as well as humans and primates.
- the present invention is characterized by providing an antioxidant composition for preventing or alleviating eye diseases, which includes the Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- the present inventors have confirmed through experiments that the Sargassum serratifolium has superior antioxidative activity among the various types of Sargassum so that it is effective in preventing, alleviating, and treating eye diseases associated with oxidative stress.
- the present inventor investigated their effects on the survival rate of oxidative stressed 661W cells (mouse-derived photoreceptor cells) in the following Experimental Example 4-1.
- the results indicate that the group treated with the only atRAL, which is an oxidative stress inducer, showed the decreased survival rate of 661W photoreceptor cells by about 55%, on the other hand, the group treated with atRAL and the Sargassum serratifolium ethanol extract together exhibited the increased survival rate of 661W photoreceptor cells by about 25% compared with the group treated with the only atRAL.
- MDA malondialdehyde
- composition of the present invention including a Sargassum serratifolium extract and a compound separated therefrom as an active ingredient may be useful as a functional material for preventing, alleviating, and treating eye diseases associated with oxidative stress.
- the Sargassum serratifolium extract according to the present invention may be used as one obtained by extracting and separating from nature using an extraction and separation method known in the art.
- the “extract” defined in the present invention may be extracted from Sargassum serratifolium using an appropriate solvent. It includes, for example, a crude extract, polar solvent extract or non-polar solvent extract of the Sargassum serratifolium.
- Any pharmaceutically acceptable organic solvent may be used as an appropriate solvent for extracting the extract from the Sargassum serratifolium .
- Water or an organic solvent may be used.
- Various solvents such as purified water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol and butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination, but the solvent may not be limited thereto.
- ethanol may be used, and more preferably, 95% ethanol may be used.
- the extraction method may use any one selected from methods including hot water extraction, chilling extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, pressing, and the like. Further, the desired extract may additionally perform a general fraction process and be purified using a general purification method.
- the method of preparing the Sargassum serratifolium extract of the present invention is not limited and may use any known method.
- a primary extract extracted by the hot water extraction or solvent extraction may be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying or spray-drying. Further, the primary extract may obtain additionally purified fractions using various types of chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography.
- the Sargassum serratifolium extract is a concept including all of the extracts, fractioned and purified materials, their dilutions, concentrates, or dried materials which are obtained in each step of extraction, fraction, or purification.
- the dried Sargassum serratifolium is powdered. Then, 95% ethanol is used as an extraction solvent to perform the extraction using the reflux cooling extraction, followed by filtration and concentration.
- SHQ, SCM and SQA compounds may be separated from the Sargassum serratifolium ethanol extract of the present invention through step-by-step processes (See Example 2).
- composition of the present invention corresponds to a pharmaceutical composition for preventing or treating eye diseases, which includes the Sargassum serratifolium extract or compound separated therefrom as an active ingredient.
- the Sargassum serratifolium extract may be a Sargassum serratifolium ethanol extract extracted with ethanol solvent, and the compound may be sargahydroquinoic acid (SHQ), sargaquinoic acid (SQA) or sagachromenol (SCM).
- SHQ sargahydroquinoic acid
- SQA sargaquinoic acid
- SCM sagachromenol
- the pharmaceutical composition of the present invention may be prepared by using pharmaceutically-suitable and physiologically-acceptable additives in addition to the active ingredient, and the additives may be an excipient, a disintegrant, a sweetener, a binder, a coating agent, an inflating agent, a glidant, a lubricant, a flavoring agent, and the like.
- the pharmaceutical composition may preferably be formulated as a pharmaceutical composition by additionally including at least one of pharmaceutically acceptable carriers in addition to the active ingredient for administration.
- a formulation of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppository, liquid, syrup, juice, a suspension, an emulsion, an ointment, an injectable liquid formulation, and the like.
- an active ingredient may be combined with an oral and non-toxic pharmaceutical acceptable inert carrier, such as ethanol, glycerol, and water in order to formulate as a type of tablets or capsules.
- a suitable binding agent, a lubricant, a disintegrant and a coloring agent may be also included in a mixture.
- the suitable binding agent includes starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweetening agents, natural or synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like, but is not limited thereto.
- the disintegrant includes starch, methylcellulose, agar, bentonite, xanthan gum, and the like, but is not limited thereto.
- a pharmaceutically acceptable carrier for a composition formulated as a liquid solution may be suitable for a sterilization and a body, and may be saline solution, sterilized water, Ringer solution, butter saline solution, albumin injection solution, dextrose solution, malto dextrin solution, glycerol, ethanol, and the mixture of at least one thereof, and other general additives, such as antioxidants, a buffering solution, and bacteriostat may be added as needed.
- tablets, granules, capsules, a pill, a dosage form for injecting such as an aqueous solution, suspension, and an emulsion may be formulated by additionally adding a diluent, a dispersing agent, a surfactant, a binding agent, and a lubricant.
- a diluent such as an aqueous solution, suspension, and an emulsion
- a dispersing agent such as a a surfactant, a binding agent, and a lubricant.
- the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) of the present invention may be included in 0.00001% by weight to 40% by weight with respect to the total weight of the composition.
- the Sargassum serratifolium extract or compound separated therefrom of the present invention may be included at a concentration of 0.1 ⁇ g/ml to 10000 ⁇ g/ml with respect to the composition, and the compound separated from the Sargassum serratifolium extract (SHQ, SCM, and SQA) may be included at a concentration of 0.1 ⁇ g/ml to 10000 ⁇ g/ml with respect to the food composition.
- the eye diseases for which the pharmaceutical composition of the present invention has therapeutic effects include age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, cystoid macular edema, and the like, but are not limited thereto.
- the Sargassum serratifolium extract or compounds separated therefrom (SHQ, SCM, and SQA) of the present invention has the effect of protecting photoreceptor cells through an excellent antioxidative activity so that it may be more effective in treating the oxidative stress-related eye disease among eye diseases.
- the oxidative stress plays a critical role in eye tissue and eye disease.
- the retina of the eye is the tissue with the fastest metabolic rate in the human body, thereby creating a tremendous amount of oxidative stress.
- the reactive oxygen species having high reactivity is generated in a significant amount, resulting in fatal eye damage.
- the age-related macular degeneration (hereinafter, referred as to “AMD”) is the most active subject among studies about eye diseases.
- the several causes of the disease include the production of reactive oxygen derivatives due to excessive oxygen use, accumulation of lipofuscin-retinoid derivatives (bisretinylethanolamine (A2E)), and oxidation by light, but the specific mechanism and treatment methods are not yet known (Zarbin, 2004, Arch Ophthalmol 122, 598-614; Kasahara et al., 2005, Invest Ophthalmol Vis Sci 46, 3426-3434).
- H 2 O 2 hydrogen peroxide
- the material capable of inhibiting or alleviating oxidative stress in the eye tissues and cells may be effectively used for preventing or treating various eye diseases (especially, macular degeneration) caused by the oxidative stress.
- the composition of the present invention includes the Sargassum serratifolium extract or compounds separated therefrom (SHQ, SCM and SQA) as an active ingredient.
- the active ingredient has the effect of protecting photoreceptor cells through an excellent antioxidative activity so that it may be useful for a pharmaceutical composition for preventing or treating eye diseases caused by the oxidative stress.
- the present invention provides a method of treating an eye disease, including administering a Sargassum serratifolium extract or a compound separated therefrom to an individual.
- the method of treating an eye disease of the present invention includes administering a Sargassum serratifolium extract or a compound separated therefrom of the present invention to an individual in a therapeutically effective amount.
- the specific therapeutically effective amount for any particular individual may vary depending on various factors well known in the medical art and other factors including the kind and degree of the response to be achieved, whether other agents are used therewith or not, specific composition, the patient's age, body weight, health conditions, gender, and diet, the time and route of administration, the secretion rate of the composition, the time period of therapy, and other drugs used in combination or coincidentally with the specific composition. Therefore, the effective amount of the composition suitable for the purpose of the present invention is preferably determined in consideration of the matters as described above.
- the mammal includes livestock such as cows, pigs, sheep, horses, dogs, and cats as well as humans and primates.
- the present invention provides a food composition for preventing or alleviating eye diseases, which includes a Sargassum serratifolium extract or a fraction thereof in an active ingredient.
- the Sargassum serratifolium extract may be a Sargassum serratifolium ethanol extract extracted with ethanol solvent, and the compound may be sargahydroquinoic acid (SHQ), sargaquinoic acid (SQA), or sagachromenol (SCM).
- SHQ sargahydroquinoic acid
- SQA sargaquinoic acid
- SCM sagachromenol
- Such a food composition may include various flavors or natural carbohydrates as well as the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient like conventional food compositions.
- SHQ, SCM and SQA Sargassum serratifolium extract or compound separated therefrom
- natural carbohydrates examples include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as general sugar including dextrin and cyclodextrin and sugar alcohols such as xylitol, sorbitol, and erythritol.
- Natural flavors thaumatin
- stevia extract e.g., rebaudioside A, glycyrrhizin, etc.
- synthetic flavors e.g., saccharin, aspartame, etc.
- the food composition of the present invention may be formulated in the same method as the pharmaceutical composition. So, the food composition may be used as a functional food or in by adding to various foods. Examples of foods to which the composition of the present invention may be added include beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- the food composition may include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like as well as the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM, and SQA) as an active ingredient.
- the food composition of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
- the eye diseases for which the food composition of the present invention has alleviative effects may be oxidative stress-related eye diseases, which include, for example, age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, cystoid macular edema, and the like, but are not limited thereto.
- age-related macular degeneration glaucoma
- diabetic retinopathy retinitis pigmentosa
- choroidal neovascular membrane uveitis
- myopic degeneration ocular tumor
- central retinal vein occlusion skin flushing
- ocular neovascularization central serous retinopathy
- dry eye syndrome central retina
- the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) of the present invention may be included in 0.00001% by weight to 40% by weight with respect to the total weight of the food composition.
- the Sargassum serratifolium extract of the present invention may be included at a concentration of 0.1 ⁇ g/ml to 10000 ⁇ g/ml with respect to the food composition, and the compound separated from the Sargassum serratifolium extract (SHQ, SCM and SQA) may be included at a concentration of 0.1 ⁇ g/ml to 10000 ⁇ g/ml with respect to the food composition.
- Such a Sargassum serratifolium extract or a compound separated therefrom (SHQ, SCM, and SQA), which is the active ingredient of the present invention, is derived from a natural material and has few side effects unlike chemicals, so that it can be safely used for long-term use for the purpose of imparting functionality of preventing or alleviating oxidative stress-related diseases.
- the present invention may be a health functional food for preventing or alleviating eye diseases, which includes a Sargassum serratifolium extract or a fraction thereof in an active ingredient.
- the Sargassum serratifolium extract may be a Sargassum serratifolium ethanol extract extracted with ethanol solvent, and the compound may be sargahydroquinoic acid (SHQ), sargaquinoic acid (SQA), or sagachromenol (SCM).
- SHQ sargahydroquinoic acid
- SQA sargaquinoic acid
- SCM sagachromenol
- the eye disease may be oxidative stress-related eye diseases, which include, for example, age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopia degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, cystoid macular edema, and the like, but is not limited thereto.
- age-related macular degeneration glaucoma
- diabetic retinopathy retinitis pigmentosa
- choroidal neovascular membrane uveitis
- myopia degeneration ocular tumor
- central retinal vein occlusion skin flushing
- ocular neovascularization central serous retinopathy
- dry eye syndrome central retinal artery occlusion
- the health functional food of the present invention may be produced and processed in the form of tablets, capsules, powders, granules, liquids, and pills for the purpose of preventing or alleviating eye diseases.
- health functional food in the present invention refers to foods produced or processed using raw materials or components that have useful functionality in the human body according to the health functional food law or means that the food is ingested for the purpose of obtaining a beneficial effect for health use such as controlling nutrients or physiological action for the structure and function of the human body.
- the health functional food of the present invention may include common food additives.
- the conformity of the “food additive” is determined, as long as there are no other regulations, in consideration with the standard and criteria of the corresponding item according to the general rule of the food additives codex and general tests approved by the Korean Ministry of Food and Drug Safety.
- the items listed on the “food additives codex” include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon color, licorice extract, crystalline cellulose, kaoliang color and guar gum; and mixed preparations such as L-glutamic acid sodium preparations, alkalis additives for noodle, preservative preparations, tar color preparations.
- a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention excipients, binders, disintegrants, and other additives can be granulated using a conventional method, and then compression molding process is performed with lubricants. Alternatively, the mixture can be directly subjected to the compression molding process.
- the health functional food in a tablet form may include sweetening agents.
- a hard capsule formulation can be produced by filling a conventional hard capsule with a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention and additives such as excipients; and a soft capsule formulation can be produced by filling a capsule support of gelatin with a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention and additives such as excipients.
- the soft capsule formulation can include plasticizers such as glycerin or sorbitol, coloring agents, and preservatives.
- a health functional food in a pill form can be produced by molding a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods.
- the health functional food in a pill form can be coated with white sugar or other coating materials, or the surface thereof can be coated with starch, talc, or other materials.
- a health functional food in a granule form can be produced by granulating a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods.
- the health functional food in a granule form can include flavoring agents and sweetening agents.
- the health functional food containing the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention has been experimentally proved to have the effect of protecting photoreceptor cells through the excellent antioxidative effects as shown in the following examples, and thus it is effective for preventing or alleviating oxidative stress-related eye diseases.
- the health functional food may be beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- Sargassum serratifolium used in the present invention was collected by scuba diving, which grows naturally in Gijang-gun, Busan or Tongyeong-si, Gyeongsangnam-do, Korea.
- Professor Chang Kyun Choi of Department of Ecological Engineering, Pukyong National University confirmed the species of Sargassum serratifolium from Gijang-gun, and Professor Kim Namgil of Department of Marine Bioscience of Gyeongsang National University confirmed the species of Sargassum serratifolium from Tongyeong-si.
- Sargassum serratifolium was naturally dried in the shady and light spot and was ground. 2 kg of the powder obtained was added to 8 L ethanol (95% ethanol). The mixture was reflux-condensed to be extracted at 70° C.
- ultrafiltration is a process that may separate substances dissolved or dispersed in the liquid by particle size or molecular size, which separates particles in the middle region of microfiltration and reverse osmosis using pressure difference as a driving force.
- Ultrafiltration membranes have pore sizes in the range of about 10 ⁇ to about 500 ⁇ and are mainly used for the separation of saccharides, proteins, living body materials, and polymer substances with particle sizes of 1 nm to 0.1 ⁇ m. Its fundamental principle is the same as that of the microfiltration. However, the membrane structure of the microfiltration has a symmetric pore structure, but the ultrafiltration membrane has a dense layer structure of asymmetric structure so that the ultrafiltration can separate smaller particles compared with the microfiltration.
- TMP transmembrane pressure drop
- Example 1-1 50 g the Sargassum serratifolium ethanol extract prepared in Example 1-1 was dissolved in 1 L a mixed solvent of water and ethanol (9:1, v/v). The mixture was poured into a separatory funnel, and 1 L n-hexane having the same amount was added to the separatory funnel. Then, the separatory funnel was shaken, and they were equilibrated. Then, the upper portion of soluble n-hexane was collected, treated with sodium sulfate (anhydrous), filtered and concentrated. This procedure was repeated 5 more times to obtain 42 g n-hexane fraction.
- the mixture was filtered through a membrane filter, and then 200 ⁇ L was injected so that they were separated in four fractions by HPLC with a Phenomenex C18 (2) (15 ⁇ m, 21.2 mm ⁇ 250 mm) column (See FIG. 1 ).
- a mixed solvent of methanol (A) and water (B) was used as the mobile phase of the chromatography, and the flow rate was set to 7 mL.
- the chromatography was set under a condition in which the column was washed at an initial concentration of A/B (90/10) to A/B (94/6) for 33 minutes, then A/B (94/6) to A/B (100/0) for 2 minutes, and A/B (100/0) for 10 minutes.
- the column was equilibrated at a concentration of A/B (90:10) for 10 minutes.
- the chromatography was performed by automatic sample injection with Autosampler 50 to 100 times, thereby preparing the primary fraction of fraction No. 1 in a large amount.
- the same instrument and column were used to increase the purity of the primary fraction obtained in large quantities.
- the chromatography was set under a condition in which the column was washed at an initial concentration of A/B (85/15) to A/B (87/13) for 26 minutes, then A/B (87/13) to A/B (100/0) for 2 minutes, and A/B (100/0) for 6 minutes. Then, the column was equilibrated at a concentration of A/B (87:13) for 10 minutes.
- the chromatography was performed by automatic sample injection with Autosampler, thereby preparing the secondary fraction of fraction No. 1 having a higher purity (See FIG. 2 ).
- the fraction No. 2 in FIG. 1 was re-chromatographed using the same HPLC instrument and column as the fraction No. 1 in Example ⁇ 2-1>.
- the chromatography was set under a condition in which the column was washed at an initial concentration of A/B (91.5/8.5) to A/B (92.2/7.8) for 26 minutes, then A/B (92.2/7.8) to A/B (100/0) for 2 minutes, and A/B (100/0) for 6 minutes. Then, the column was equilibrated at a concentration of A/B (91.5:8.5) for 10 minutes.
- the chromatography was performed by automatic sample injection with Autosampler 50 to 100 times, thereby preparing the secondary fraction of fraction No. 2 in a large amount (See FIG. 4 ).
- the fraction No. 2 showed three peaks. Among them, the peak No. 2 (Frc2-2) was re-purified to obtain a chromatogram as illustrated in FIG. 5 (126 mg). The separated product was analyzed by NMR and found to be sargachromenol (hereinafter, referred to as “SCA”) (See FIG. 5 ).
- SCA sargachromenol
- the fraction No. 3 in FIG. 1 was re-chromatographed using the same HPLC instrument and column as the fraction No. 1 in Example ⁇ 2-1>.
- the chromatography was set under a condition in which the column was washed at an initial concentration of A/B (93.4/6.6) to A/B (93.8./6.2) for 20 minutes, then A/B (93.8/6.2) to A/B (100/0) for 2 minutes, and A/B (100/0) for 6 minutes. Then, the column was equilibrated at a concentration of A/B (93.8:6.2) for 10 minutes.
- the chromatography was performed by automatic sample injection with Autosampler 50 to 100 times, thereby preparing the secondary fraction of fraction No. 3 in a large amount (See FIG. 6 ).
- the fraction No. 3 showed four peaks. Among them, the peak No. 4 (Frc3-4) was re-purified to obtain a chromatogram as illustrated in FIG. 7 (171 mg).
- the separated product was analyzed by NMR and found to be sargaquinoic acid (hereinafter, referred to as “SQA”) (See FIG. 7 ).
- RAW 264.7 cells (5 ⁇ 10 4 cells/well) were treated with the Sargassum serratifolium ethanol extract or hexane fraction thereof, respectively, of the present invention prepared in Example 1, and cultured in DMEM medium for 24 hours. 95 ⁇ L the medium and 5 ⁇ L the MTS solution were placed in a 96-well plate and were reacted for 3 hours. Then, the absorbance thereof was measured at 490 nm using a microplate reader. The experiments were repeated three times, and the mean value thereof was used as its measurement value.
- the results indicate that the cytotoxicity of Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention to the macrophage line (RAW 264.7 cells) did not show up to a concentration of 8 ⁇ g/mL.
- Nitric oxide, reactive oxygen species (ROS), antioxidative activity by DPPH method, ABTs antioxidative activity, and hydroxyl radical were measured so as to evaluate the antioxidative activity of Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention prepared in Example 1.
- RAW 264.7 cells (7 ⁇ 10 4 cells/well) were inoculated into 96-well plates using DMEM medium.
- New medium containing samples Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1
- LPS (1 ⁇ g/mL) were co-treated and were cultured for 24 hours.
- the Griess reagent was used, so that the amount of NO produced was measured in the form of NO 2 ⁇ present in the cell culture medium.
- 100 ⁇ L the cell culture supernatant and 100 ⁇ L Griess reagent [1% sulfanilamide, 0.1% naphthyl ethylenediamine in 5% phosphoric acid] were mixed and reacted on a 96-well plate for 10 minutes. Then, the absorbance thereof was measured at 540 nm using an ELISA reader. Standard concentration curves were obtained by serial dilution of sodium nitrite (NaNO 2 ).
- the results show that the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with the Sargassum serratifolium ethanol extract and hexane fraction thereof in macrophages, respectively.
- the EC 50 values of the ethanol extract and hexane fraction were 1.72 ⁇ g/mL and 1.51 ⁇ g/mL, respectively.
- DCFH-DA was used to measure the amount of active oxygen so as to examine the inhibitory effect of Sargassum serratifolium extract on the production of reactive oxygen species (RAW 264.7 cells).
- Samples Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1 and LPS (1 ⁇ g/mL) were co-treated and were cultured for 2 hours. Then, they were treated with 20 ⁇ M DCFH-DA and were cultured for 30 minutes. Thereafter, the cell culture supernatant was collected and measured by spectrofluorometry at an excitation wavelength of 485 nm and a radiation wavelength of 523 nm.
- the results show that the production of reactive oxygen species induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with the Sargassum serratifolium ethanol extract and hexane fraction thereof in macrophages, respectively.
- the IC 50 values of the ethanol extract and hexane fraction were 0.92 ⁇ 0.09 ⁇ g/mL and 0.88 ⁇ 0.08 ⁇ g/mL, respectively.
- the DPPH method (Blois, M. S.: Antioxidant determination by the use of a stable free radical, Nature, 26, 1199-1200, 1958) was used to measure the antioxidant effect of Sargassum serratifolium in vitro.
- the DPPH (1,1-diphenyl picrylhydrazyl) method is a method of measuring the antioxidative effect by hydrogen donating ability depending on the degree of discoloration of deep purple color by reduction due to a physiologically active substance having an antioxidative activity such as tocopherol, ascorbate, flavonoid compounds, aromatic amines, Maillard-type browning agent and peptide.
- 100 ⁇ l DPPH having a concentration of 200 ⁇ M and 100 ⁇ l the sample were mixed in a 96-well plate, and they reacted at room temperature for about 30 minutes. Then, the absorbance thereof was measured at 517 nm using a microplate reader. BHT was used as a positive control. The concentration thereof was compared to the same as that of the sample.
- DPPH radical scavenging activity was calculated by the method as described below.
- Radical scavenging activity(%) ( A DPPH ⁇ A sample )/ A DPPH ⁇ 100
- the ABTs assay is similar to the DPPH assay but differs in that antioxidative activity is measured by generating free radicals through chemical reactions. ABTs are reacted with potassium persulfate to generate ABTs anion radicals, which react with H-donors such as phenolic compounds to be converted to colorless ABTs. Accordingly, the degree of antioxidative activity may be determined by measuring the amount of ABTs consumed by reacting with a sample containing a phenolic compound.
- ABTs antioxidative activity was measured by partially modified Van den Berg (1999) and others using the discoloration of ABTs radical-specific green color by antioxidants.
- Potassium persulfate was added to 7 mM ABTS solution at a final concentration of 2.4 mM. They reacted in the dark for 12 hours to 16 hours at R/T so as to produce ABTs cations.
- the resulting ABTs cation was diluted to be used, having an absorbance value of 0.7 ⁇ 0.02. 10 ⁇ L of the sample was treated with 190 ⁇ L ABTs+ working solution and reacted for 6 minutes in a 96-well plate. The absorbance thereof was measured at 732 nm.
- the radical scavenging activity was calculated from the measured values as follows. BHT was used as a positive control. The antioxidant ability of the sample is determined by the IC 50 value in which 50% of ABTs was reduced.
- Percentage inhibiting activity I (%) ( A control A sample )/ A control / ⁇ 100
- Control (blank sample)
- a control Sample measurement value
- Hydroxyl radicals are the most reactive radicals among oxygen radicals, which occur during aerobic metabolism in the human body. These radicals damage peripheral cells to create collateral living body molecules.
- a deoxyribose test was performed so as to measure the ability to scavenge hydroxyl radicals. Hydroxyl radicals attack deoxyribose to create small fragments. Some of which are pink when added with TBA (thiobarbituric acid) under an acidic pH environment, so the degree of damage by hydroxyl radicals is measured by absorbance at 532 nm.
- TBA thiobarbituric acid
- Fe2+-EDTA mixture which is an oxidized form of ferric chloride (FeCl 3 ) and ethylenediamine tetraacetic acid (EDTA).
- EDTA ethylenediamine tetraacetic acid
- 0.5 ml of 20 mM hydrogen peroxide (H 2 O 2 ) was added to form Fe3+-EDTA and HO radical. They were then incubated at 37° C. for 1 hour. After the incubation, 1 ml of 2.8% Trichloroacetic acid (TCA) and 1% TBA, respectively, were added. The mixture was boiled in boiling water at 100° C. for 30 minutes. The absorbance thereof was measured.
- BHT (2 ⁇ g/ml to 25 ⁇ g/ml) was used as a positive control.
- Hydroxyl radical scavenging ability(%) ( A control ⁇ A sample )/ A control ⁇ 100
- Control (blank sample)
- a control Sample measurement value
- 661W photoreceptor cells were cultured in 96-wells at a concentration of 3 ⁇ 10 3 cells/well. Then, they were treated with 1.0 ⁇ g/ml Sargassum serratifolium ethanol extract or compounds separated therefrom (sargahydroquinoic acid (SHQ), sargachromenol (SCM), and sargaquinoic acid (SQA)) at a concentration of 1.0 ⁇ M and cultured for 24 hours. Then, the medium was replaced with medium containing MTS reagent. Then, they were cultured for 1 hour. Cell viability was measured by measuring the absorbance at 490 nm and comparing the results. The cell viability was analyzed by Celltiter 96 Aqueous One solution assay kit (Promega).
- the results indicate that no cytotoxicity was observed in the 661W photoreceptor cells in both Sargassum serratifolium ethanol extract (1 ⁇ g/ml) and the compound separated therefrom (1 ⁇ M).
- the atRAL is an intermediate metabolite of the visual cycle and is an aldehyde-type compound.
- the atRAL may induce excessive oxidative stress in cells. Therefore, when 661W photoreceptor cells were treated with the atRAL compound to induce the oxidative stress, the protective effect of the Sargassum serratifolium ethanol extract and the compound separated therefrom of the present invention on 661W photoreceptor cells was examined.
- 661W photoreceptor cells were cultured in 96-wells at a concentration of 3 ⁇ 10 3 cells/well and treated with atRAL having a concentration of 1.8 ⁇ M (Sigma Aldrich, St. Louis, Mo., USA) for 24 hours. Then, the medium was replaced with medium containing MTS reagent, and they were cultured for 1 hour. The absorbance thereof was measured at 490 nm, and the results were compared to determine cell viability. The cell viability thereof was measured by Celltiter 96 Aqueous One solution assay kit (Promega).
- the results indicate that the cell viability of 661W photoreceptor cells was reduced by about 55% in the only atRAL-treated group, whereas the cell viability in the experimental group treated with 0.5 ⁇ g/mL of Sargassum serratifolium ethanol extract and atRAL was increased by about 25% compared to the experimental group treated with the only atRAL.
- the cell viability of 661W photoreceptor cells was more than 90% in the experimental group treated with 0.5 ⁇ M sargahydroquinoic acid (SHQ), sargachromenol (SCM), and sargaquinoic acid (SQA), respectively, so that no significant difference was found between the atRAL-treated group and the untreated group.
- SHQ sargahydroquinoic acid
- SCM sargachromenol
- SQA sargaquinoic acid
- DCFH-DA 2′,7′-dichlorodihydrofluorescein diacetate
- AtRAL (1.8 ⁇ M) and Sargassum serratifolium ethanol extract (0.5 ⁇ g/mL), sargachromenol (0.5 ⁇ M), sargahydroquinoic acid (0.5 ⁇ M) or sargaquinoic acid (1.0 ⁇ M) were added to medium mixed with DCFH-DA (20 ⁇ M), and the photoreceptor cells were treated with them and cultured for 30 minutes. Then, the cells were washed with PBS, and the cells were recovered. The cells expressing the fluorescence were measured using flow cytometry.
- the results demonstrate that the cells treated with atRAL only had a fluorescence expression level having about 80% higher than that of the control group.
- the fluorescence expression level was reduced by about 75% compared to the group treated with atRAL only.
- the fluorescence expression levels were reduced by 76%, 77%, and 73%, respectively, and there was no difference from the control group untreated with atRAL.
- the Sargassum serratifolium ethanol extract and compound separated therefrom were found to effectively inhibit atRAL-induced oxidative stress, thereby protecting photoreceptors.
- samples of each of Sargassum serratifolium ethanol extract and the compounds separated therefrom were mixed with a specific amount of atRAL (1.8 ⁇ M) and Sargassum serratifolium ethanol extract (0.5 ⁇ g/mL), sargachromenol (0.5 ⁇ M), sargahydroquinoic acid (0.5 ⁇ M) or sargaquinoic acid (1.0 ⁇ M).
- the photoreceptor cells were treated with mixtures. Then, they were cultured for 2 hours. The cells were then washed with PBS and the intracellular proteins were recovered. The number of proteins denatured by the lipid peroxides in cells was analyzed by protein immunoassay using MDA immunoblot kit (Cell biolabs).
- the results indicate that the cells treated with atRAL only showed an increase in expression level of protein denatured by MDA compared with the control, whereas the group treated with atRAL and Sargassum serratifolium ethanol extract having 0.5 ⁇ g/mL of the present invention has decreased expression level of MDA peroxidase protein compared with the group treated with atRAL only.
- the expression level of MDA peroxidase protein was similarly decreased in the experimental groups treated with atRAL and compounds separated from Sargassum serratifolium ethanol extract, respectively.
- the Sargassum serratifolium ethanol extract and compound separated therefrom effectively inhibit atRAL-induced oxidative stress so that the photoreceptors are protected by inhibiting peroxidation of cell membrane lipid component.
- the toner (skin) containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
- the toner (lotion) containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
- toner formulation of the present invention Composition Content(weight %) Sargassum serratifolium ethanol 1 to 3 extract or hexane fraction Glyceryl stearate SE 1.5 Cetearyl alcohol 1.5 Lanolin 1.5 Polysorbate 60 1.3 Sorbitan stearate 0.5 Hardened vegetable oil 4.0 Mineral oil 5.0 Trioctanoin 2.0 Dimethicone 0.8 Tocopherol acetate 0.5 Carboxyvinyl polymer 0.12 Glycerin 5.0 1,3-Butylene glycol 3.0 Sodium hyaluronate 5.0 Triethanolamine 0.12 Unicide-U 13 0.02 Flavor Trace Distilled water Residue Total 100
- the nourishing cream containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
- the massage cream containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
- the pack containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Marine Sciences & Fisheries (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
Abstract
The present invention relates to an antioxidant composition and, more specifically, to an antioxidant composition including a Sargassum serratifolium extract or a fraction thereof as an active ingredient, in which the antioxidant composition is a useful material (substance) that can be added to medicines, cosmetics, foods, animal feeds, and the like. The present invention also relates to a pharmaceutical composition for preventing or treating eye diseases, a food composition for alleviating eye diseases, and a health functional food, each of which includes a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
Description
- The present invention relates to an antioxidant composition, and more particularly to an antioxidant composition including a Sargassum serratifolium extract or fraction thereof as an active ingredient, which is a useful substance (material) that can be added to medicines, cosmetics, foods, animal feeds and the like. The present invention also relates to a pharmaceutical composition for preventing or treating eye diseases, a food composition for alleviating eye diseases, and a health functional food, each of which includes a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- Anti-oxidation refers to the prevention of various oxidations which occur in the body. Lipids present as biological membranes and lipoproteins are attacked by free radicals in the body so as to form various kinds of peroxides. Such peroxides, decomposition products, and like are highly reactive to change the structure and function of the surrounding biomolecules, thereby resulting in the aging phenomenon and various chronic diseases.
- The body contains various antioxidant defense mechanisms which can neutralize such free radicals to protect the body. Human diseases and aging are caused by the oxidation of O2 − (superoxide), NO (nitric oxide), NO2 (nitrogen dioxide), OH (hydroxyl), ROO (proxyl), RO (alkoxyl), HO2 − (hydroperoxyl) radical, and the like that occur during metabolism in the body. As a mean of protecting the living body from free radicals such as these harmful radicals, superoxide dismutase (SOD), an antioxidant enzyme, reduces superoxide radicals to H2O2 in the body. For H2O2 caused herein, antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GSH-px) and antioxidants such as vitamin C, vitamin E, and glutathione remove the free radicals to protect the body against oxidative damage.
- However, when the antioxidant defense system is weak to such an extent that cannot control the free radical generation, the oxidative stress and damage of tissues are promoted, and the excess free radicals and lipid peroxides generated in the body increase damage caused by oxidative stress such as protein oxidation and DNA damage. Currently reported, in 2003 the leading causes of death in South Korea were cancer, cerebrovascular disease, cardiovascular disease, and diabetes in order (Korea National Statistical Office: The cause of death statistics, 2003 and Annual Report of on the Cause of Death Statistics. Korea National Statistical Office, 2004). It is known that reactive oxygen species (ROS) may be the main cause of chronic degenerative diseases such as cardiovascular disease, diabetes, cancer, degenerative neuropathy, and aging, and antioxidants may remove the reactive oxygen species to help to prevent chronic degenerative diseases.
- The active oxygens (O2 −, H2O2, OH and 1O2) generated during the human physiological process are highly reactive, and the free radical reactions caused by them results in the destruction of major macromolecules including lipids (Davies, K J A and Goldberg, A L., J. Biol. Chem., 262, pp. 8220-8226, 1987). Their generation is increased by various causes that result in abnormalities in normal metabolism, photosensitization reaction, drug metabolism, and another cell metabolism. Living organisms are always exposed to the harmful effects of free radical reactions induced by them.
- In particular, as cells age, harmful effects due to these harmful radicals are continuously accumulated, resulting in diseases related to various adult diseases, according to aging, such as cancer, atherosclerosis, heart disease, skin aging, and eye diseases, as well as overall cell aging. Thus, they are suggested as a cause of human disease and aging.
- Meanwhile, eyes are affected by oxidative stress due to ultraviolet rays, radiation, smoking, environmental pollution of living bodies, or systemic oxidative stress due to foreign substances in the blood in the body. In the eye tissue, reactive oxygen species (ROS) are generated by respiration, redox enzymes, and photochemical reactions in the mitochondria. In the mitochondrial electron transport system in cells, electrons received from NADH or succinate are transported by step along with each electron transport complex, resulting in an O2 reduction to become water. However, when electrons are released at the intermediate stage of the electron transport system to be immediately transferred to oxygen, superoxide (O2 −) is formed non-enzymatically. Nitric oxide synthase (NOS) is converted into L-arginine L-citrulline, which produces nitric oxide. This nitric oxide reacts with superoxide to generate highly reactive peroxynitrite (ONOOK). Further, photosensitizers such as riboflavin generate superoxide, hydroxyl radical, hydrogen peroxide (H2O2) and the like by photochemical reaction.
- The eye tissues include antioxidant enzymes such as superoxide dismutase (SOD) including copper (Cu), zinc (Zn), and manganese (Mn), catalase, and glutathione peroxidase containing selenium (Se), lipid-soluble antioxidant compounds such as tocopherol and carotenoids, and water-soluble antioxidants such as ascorbic acid and reduced glutathione, which are involved in the removal of active oxygen. Further, the eye tissues include glutathione reductase involved in the reduction of oxidized glutathione, thioredoxin and ascorbic acid free radical enzyme which removes ascorbic acid free radicals.
- It is known that oxidative stress, which is caused by breaking the balance between the production system and the scavenging system, plays a critical role in the eye tissues and eye diseases. The retina of eyes is a tissue that has a high metabolic rate in the human body, causing a massive amount of oxidative stress. Further, eyes are exposed to high-energy ultraviolet rays, thereby producing a significant amount of active oxygen, which is highly reactive to result in fatal damage such as macular degeneration.
- Age-related macular degeneration (hereinafter, referred as to “AMD”) is the most active subject among studies about eye diseases. It is reported that more than 8 million people now have dry AMD, a type of this disease in the United States, and more than 3 million people are blinded by the disease each year. The several causes of disease include the production of reactive oxygen derivatives due to excessive oxygen use, accumulation of lipofuscin-retinoid derivatives (bisretinylethanolamine (A2E)), and oxidation by light, but the specific mechanism and treatment methods are not yet known (Zarbin, 2004, Arch Ophthalmol 122, 598-614; Kasahara et al., 2005, Invest Ophthalmol Vis Sci 46, 3426-3434).
- The light energy information received by the eye passes through the G-protein coupled receptor (GPCR) signal transferring process, thereby closing the cation channel involved in cGMP, and thus the visual cell becomes electrically polarized so that the information is transmitted to the brain in the form of electric energy. The retinal is changed from 11-cis structure to all-trans structure by light but is again regenerated in 11-cis structure by several proteins and enzymatic reactions. Thus, a series of reactions that the retinal reacts with light and are recycled by enzymes is called the visual cycle or retinoid cycle of the eye. The retinal reacted with light in the visual cell is hydrolyzed to be transferred to the retinal pigment epithelium so that the retinal becomes a substrate for the series of reactions. The recycling of retinal in the eye is a critical factor for continuous viewing of vertebrates.
- Photoreceptor cells in the retina are essential optic neurons that accept stimulation of light to convert into electrical signals. Rhodopsin in photoreceptor cells includes an optic and 11-cis-retinal (hereinafter, simply abbreviated as “11cRAL”). The 11cRAL passes through the interphotoreceptor matrix and is then transported to photoreceptor cells. Then, the 11cRAL binds to the opsin protein to form a visual purple called rhodopsin. Photoreceptor cells with rhodopsin are critical for sight in the dark because they may capture even tiny amounts of light. In rhodopsin, photoactivation causes the 11cRAL to be decomposed into all-trans-retinal (hereinafter, simply abbreviated as ‘atRAL’) and opsin. The atRAL generated herein is gradually reduced to 11cRAL by a visual cycle generated in photoreceptor cells and retinal pigment epithelium. Then, the 11cRAL binds to the opsin to re-synthesize rhodopsin (Jin M, et al., Cell, 2005).
- The atRAL and 11cRAL are intermediate metabolites of the visual cycle and are aldehyde-type compounds, which may induce excessive oxidative stress in cells so that they are strictly controlled by several enzymes in each step of the visual cycle. Mutations or dysfunctions or overexposure to the light of enzymes responsible for the visual cycle result in over-production of atRAL and accumulation of atRAL in photoreceptor cells, thereby leading to the death of photoreceptor cells. Patients with visual impairment have gene-mutation of enzymes which play critical roles in the visual cycle such as atROL dehydrogenase, which reduces atRAL to all-trans-retinol (hereinafter, simply abbreviated as “atROL”) and ATP-binding cassette sub-family A member 4 (Abca4) and interphotoreceptor retinoid binding protein (IRBP), which aid retinol migration between photoreceptor cells and retinal pigment epithelium, and thus photoreceptor cells in the retina is degraded (Busskamp V, et al., Science, 2010; Allikmets R, et al. Science, 1997; Jin M, et al., Cell, 2005; Jin M, et al. The Journal of Neuroscience, 2009; Maeda A, et al. The Journal of biological chemistry, 2009).
- In addition, the mouse animal model confirmed that the genetic defect of each enzyme increases the production of atRAL in the retina. It is thus considered that the regulation of atRAL is very critical in optic nerve tissues. 661W cells are mouse-derived photoreceptor cells, which have been widely used to study optic nerve degeneration, optic nerve protection, and the like (Tan E, et al., Investigative ophthalmology & visual science, 2004). In particular, it has been studied mainly for the response to oxidative stress such as the stimulation of ultraviolet rays and hydrogen peroxide as well as the protective effect on the optic nerve of various compounds (Kanan Y, et al., Cell Mol Neurobiol, 2015; Krishnamoorthy R R, et al., The Journal of Biological Chemistry, 1999).
- Accordingly, studies have been conducted on finding a candidate substance which is expected to be useful in various diseases caused by oxidative damage by inhibiting the free radical reaction in the body due to reactive oxygen metabolites or removing harmful active oxygen accumulated in the human body.
- Many studies have been actively conducted to prepare safe and powerful antioxidants by separating components with antioxidative activity from natural products all over the world. Until now, studies and reports have been conducted on various natural antioxidants such as soybean (Duh et al., 1997), oilseed (Deiana et al., 1999), herb (Kitts et al., 2000), tea (Roedig-Penman and Gordon, 1997), fruit of strawberries (Wang and Jiao, 2000), ginkgo extract (Gohil et al., 2000), ginseng extract (Keum et al., 2000), fruits and vegetables (Cao et al., 1996; Wang et al., 1996, Brown and Rice-Evans, 1998).
- In addition, it is reported that resveratrol, which is abundant in the grape skin, is antioxidant to decrease the death of rat pheochromocytoma (PC12) cells induced by reactive oxygen species (M. V. Clement et al., 1998).
- However, there are many antioxidants in the natural world, which have not yet been identified. If these new substances are discovered, they can be used as useful materials for foods, medicines, and cosmetics.
- Accordingly, the present inventors have searched for a natural substance having excellent antioxidative activity without any side effect on the living body and focused on Sargassum serratifolium. Thus, the present inventors examined the antioxidative effect of Sargassum serratifolium. As a result, the present inventors confirmed that a Sargassum serratifolium extract and fraction thereof has excellent scavenging ability of nitric oxide and intercellular reactive oxygen species, DPPH radical scavenging activity, ABTS cation scavenging activity, and hydroxyl radical (—OH) scavenging activity, thereby completing the present inventions.
- In addition, the present inventors have examined the protective effect of mouse-derived 661W photoreceptor cells using the Sargassum serratifolium extract and the compounds separated therefrom. As a result, it has been found that the experimental group, which is treated with Sargassum serratifolium extract and the compounds separated therefrom of the present invention, together with atRAL (oxidative stress inducer) shows a significant increase in cell viability compared to the experimental group treated with atRAL alone and inhibitory effect of reactive oxygen species (ROS) production and malondialdehyde (hereinafter, simply abbreviated as “MDA”) peroxide protein production, thereby completing the present invention.
- An object of the present invention is to provide a composition that has excellent antioxidative activity and is stable to the human body over long-term use, using a natural marine algae extract.
- Another object of the present invention is to provide a food and feed additive composition that has excellent antioxidative activity and is stable to the human body over long-term use, using a natural marine algae extract.
- Still another object of the present invention is to provide a cosmetic composition that has excellent antioxidative activity and is stable to the human body over long-term use, using a natural marine algae extract.
- Yet still another object of the present invention is to provide a pharmaceutical composition that is useful for preventing or treating eye disease and is stable to the human body over long-term use, using a natural marine algae extract.
- Yet still another object of the present invention is to provide a food composition that is useful for preventing or alleviating eye disease and is stable to the human body over long-term use, using a natural marine algae extract.
- Yet still another object of the present invention is to provide a health functional food composition that is useful for preventing or alleviating eye disease and is stable to the human body over long-term use, using a natural marine algae extract.
- In order to achieve the objects, the present invention provides a composition having an antioxidative activity, the composition including a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- According to one aspect of the present invention, the extract may be extracted with at least one solvent selected from the group consisting of lower alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, water, and hexane.
- According to one aspect of the present invention, the lower alcohols having 1 to 4 carbon atoms may include ethanol.
- According to one aspect of the present invention, the fraction may be a hexane fraction of the Sargassum serratifolium extract.
- According to one aspect of the present invention, the composition may include a Sargassum serratifolium extract or a fraction thereof in a concentration of 0.1 μg/ml to 1000 μg/ml.
- According to one aspect of the present invention, the composition may be a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition.
- Further, the present invention is to provide an antioxidant or anti-aging cosmetic composition including a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- According to one aspect of the present invention, the extract may be extracted with an ethanol solvent.
- According to one aspect of the present invention, the fraction may be a hexane fraction of the Sargassum serratifolium extract.
- According to one aspect of the present invention, the cosmetic composition may have one formation selected from the group consisting of a toner, a gel, soluble liquid, a milky lotion, a nutrition cream, a massage cream, an essence, an oil-in-water type emulsion, a water-in-oil type emulsion, a paste-like anhydrous product, a solid anhydrous product, an oil dispersion in aqueous phase using small spheres, an ionic lipid vesicle, a nonionic lipid vesicle, ointment, cleansing foam, cleansing water, pack, body oil, oil-in-water type makeup base, water-in-oil type makeup base, foundation, skin cover, lipstick, lip gloss, face powder, twin cake, eyeshadow, mascara, cheek color, and eyebrow pencil.
- Further, the present invention is to provide a pharmaceutical composition for preventing or treating an eye disease, the pharmaceutical composition including a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- According to one aspect of the present invention, the extract may be extracted with an ethanol solvent.
- According to one aspect of the present invention, the compound may be sargahydroquinoic acid, sargaquinoic acid, or sagachromenol.
- According to one aspect of the present invention, the eye disease may be one selected from the group consisting of age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, and cystoid macular edema.
- Further, the present invention is to provide a food composition for preventing or alleviating an eye disease, the food composition including a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- According to one aspect of the present invention, the extract may be the Sargassum serratifolium ethanol extract, and the compound may be sargahydroquinoic acid, sargaquinoic acid, or sargachromenol.
- Further, the present invention is to provide a health functional food for preventing or alleviating an eye disease, the health functional food including a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- According to one aspect of the present invention, the extract may be the Sargassum serratifolium ethanol extract, and the compound may be sargahydroquinoic acid, sargaquinoic acid or sagachromenol.
- According to one aspect of the present invention, the food may be one selected from the group consisting of a beverage, meat, chocolate, a food, snack, pizza, ramen, another noodle, a gum, candy, ice cream, an alcoholic beverage, a vitamin complex, and a health supplement food.
- According to one aspect of the present invention, the Sargassum serratifolium extract or the compound separated therefrom may have an effect of protecting a photoreceptor cell by antioxidative activity.
- A Sargassum serratifolium extract or a fraction thereof according to the present invention has excellent DPPH radical scavenging activity, ABTS cation scavenging activity, and hydroxyl radical (—OH) scavenging activity as well as the intercellular nitric oxide and reactive oxygen species scavenging ability. Thus, a composition containing it as an active ingredient has an antioxidative activity, which may be useful for functional additive materials for medicines, cosmetics, foods, animal feeds, and the like.
- Further, the Sargassum serratifolium extract or a compound derived therefrom according to the present invention has an excellent effect of protecting photoreceptor cells on the retina of the eye. Thus, a composition containing it as an active ingredient may be useful for medicine and health functional food materials for preventing, alleviating, or treating eye diseases.
- In particular, Sargassum serratifolium may be edible as a natural material, so that the composition of the present invention including the extract derived therefrom and fraction or compound derived therefrom has an advantage of safety over long-term use.
-
FIG. 1 illustrates four fraction chromatograms obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 2 illustrates a secondary fraction chromatogram of the fraction No. 1 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 3 illustrates a chromatogram of sargahydroquinoic acid identified by NMR analysis on a product obtained by purifying a secondary fraction of the fraction No. 1 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 4 illustrates the results of confirming three peaks in the secondary fraction chromatogram of the fraction No. 2 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 5 illustrates a chromatogram of sagachromenol identified by NMR analysis on a product obtained by purifying 2nd peak of the secondary fraction of the fraction No. 2 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 6 illustrates the results of confirming four peaks in the secondary fraction chromatogram of the fraction No. 3 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 7 illustrates a chromatogram of sargaquinoic acid identified by NMR analysis on a product obtained by purifying 4th peak of the secondary fraction of the fraction No. 2 of the four fractions obtained from a Sargassum serratifolium n-hexane fraction. -
FIG. 8 illustrates the results of measuring the cytotoxicity of macrophage (RAW 264.7) according to treatment concentration of a Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention. -
FIG. 9 illustrates the results of measuring LPS-induced nitric oxide production in macrophages according to treatment concentration of a Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention. -
FIG. 10 illustrates the results of measuring LPS-induced reactive oxygen species (ROS) in macrophages according to treatment concentration of a Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention. -
FIG. 11 illustrates the results of measuring the cytotoxicity of 661W, photoreceptor cells according to treatment with a Sargassum serratifolium ethanol extract (hereinafter, simply abbreviated as “SSE”) of the present invention. -
FIG. 12 illustrates the results of measuring the cytotoxicity of 661W, photoreceptor cells according to treatment with a compound selected from SSE ((sargahydroquinoic acid (hereinafter, simply abbreviated as “SHQ”), sargaquinoic acid (hereinafter, simply abbreviated as “SQA”) or sargachromenol (hereinafter simply abbreviated as “SCM”)). -
FIG. 13 illustrates the results of measuring cell viability of 661W cells according to the combined treatment of 661W photoreceptor cells derived from mice with an atRAL compound as oxidative stress inducer, a Sargassum serratifolium ethanol extract (SSE) and compounds separated therefrom of the present invention (SHQ, SCM, SQA), respectively. *P<0.05 refers to significance for non-treatment, and #P<0.05, ##P<0.01 and ### P<0.001 refer to significance for atRAL treatment. -
FIG. 14 illustrates the results of measuring the inhibitory level of reactive oxygen species production according to the combined treatment of 661W photoreceptor cells derived from mice with an atRAL compound as oxidative stress inducer, a Sargassum serratifolium ethanol extract (SSE) and compounds separated therefrom of the present invention (SHQ, SCM, SQA), respectively. -
FIG. 15 illustrates the results of the protein immunoassay on an amount of malondialdehyde (MDA) protein in cells according to the combined treatment of 661W photoreceptor cells derived from mice with an atRAL compound as oxidative stress inducer, a Sargassum serratifolium ethanol extract (SSE) and compounds separated therefrom of the present invention (SHQ, SCM, SQA), respectively. - Evaluation of Cytotoxicity of Sargassum serratifolium Ethanol Extract and n-Hexane Fraction Thereof of the Present Invention
- RAW 264.7 cells (5×104 cells/well) were treated with the Sargassum serratifolium ethanol extract or hexane fraction thereof, respectively, of the present invention prepared in Example 1, and cultured in DMEM medium for 24 hours. 95 μl the medium and 5 μl the MTS solution were placed in a 96-well plate and were reacted for 3 hours. Then, the absorbance thereof was measured at 490 nm using a microplate reader. The experiments were repeated three times, and the mean value thereof was used as its measurement value.
- As illustrated in
FIG. 8 , the results indicate that the cytotoxicity of Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention to the macrophage line (RAW 264.7 cells) did not show up to a concentration of 8 μg/mL. - Antioxidative Activity of Sargassum serratifolium Ethanol Extract and n-Hexane Fraction Thereof of the Present Invention
- Nitric oxide, reactive oxygen species (ROS), antioxidative activity by DPPH method, ABTs antioxidative activity, and hydroxyl radical were measured so as to evaluate the antioxidative activity of Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention prepared in Example 1.
- <2-1> Measurement of Nitric Oxide
- RAW 264.7 cells (7×104 cells/well) were inoculated into 96-well plates using DMEM medium. New medium containing samples (Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1) and LPS (1 μg/mL) were co-treated and were cultured for 24 hours. The Griess reagent was used, so that the amount of NO produced was measured in the form of NO2− present in the cell culture medium. 100 μL the cell culture supernatant and 100 μL Griess reagent [1% sulfanilamide, 0.1% naphthyl ethylenediamine in 5% phosphoric acid] were mixed and reacted on a 96-well plate for 10 minutes. Then, the absorbance thereof was measured at 540 nm using an ELISA reader. Standard concentration curves were obtained by serial dilution of sodium nitrite (NaNO2).
- As illustrated in
FIG. 9 , the results indicate that the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with a Sargassum serratifolium ethanol extract and a hexane fraction thereof in macrophages, respectively. The EC50 values of the ethanol extract and hexane fraction were 1.72 μg/mL and 1.51 μg/mL, respectively. - <2-2> Measurement of Intracellular Reactive Oxygen Species
- DCFH-DA was used to measure the amount of active oxygen so as to examine the inhibitory effect of the Sargassum serratifolium extract on the production of reactive oxygen species (RAW 264.7 cells). Samples (Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1) and LPS (1 μg/mL) were co-treated and were cultured for 2 hours. Then, they were treated with 20 μM DCFH-DA and were cultured for 30 minutes. Thereafter, the cell culture supernatant was collected and measured by spectrofluorometry at an excitation wavelength of 485 nm and a radiation wavelength of 523 nm.
- As illustrated in
FIG. 10 , the results indicate that the production of reactive oxygen species induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with a Sargassum serratifolium ethanol extract and a hexane fraction thereof in macrophages, respectively. The IC50 values of the ethanol extract and hexane fraction were 0.92±0.09 μg/mL and 0.88±0.08 μg/mL, respectively. - <2-3> Measurement of Antioxidative Activity by DPPH Method
- The DPPH method (Blois, M. S.: Antioxidant determination by the use of a stable free radical, Nature, 26, 1199-1200, 1958) was used to measure the antioxidant effect of Sargassum serratifolium in vitro. The DPPH (1,1-diphenyl picrylhydrazyl) method is a method of measuring the antioxidative effect by hydrogen donating ability according to the degree of discoloration of deep purple color by reduction due to a physiologically active substance having an antioxidative activity such as tocopherol, ascorbate, flavonoid compounds, aromatic amines, Maillard-type browning agent, and peptide. For the measurement, 100 μl DPPH having a concentration of 200 μM and 100 μl the sample were mixed in a 96-well plate, and they reacted at room temperature for about 30 minutes. Then, the absorbance thereof was measured at 517 nm using a microplate reader. BHT was used as a positive control. The concentration was compared at the same as that of the sample.
- DPPH radical scavenging activity was calculated by the method as described below.
-
Radical scavenging activity(%)=(A DPPH −A sample)/A DPPH×100 - As shown in Table 1, the results indicate that IC50 values of Sargassum serratifolium ethanol extract and hexane fraction thereof were 11.17±0.42 μg/mL and 9.05±0.21 μg/mL, respectively, and these values were lower than those of BHT used as a positive control (See Table 1).
- <2-4> ABTs Assay
- The ABTs assay is similar to the DPPH assay but differs in that antioxidative activity is measured by generating free radicals through chemical reactions. ABTs are reacted with potassium persulfate to generate ABTs anion radicals, which react with H-donors such as phenolic compounds to be converted to colorless ABTs. Accordingly, the degree of antioxidative activity may be determined by measuring the amount of ABTs consumed by reacting with a sample containing a phenolic compound.
- ABTs antioxidative activity was measured by partially modified Van den Berg (1999) and others using the discoloration of ABTs radical-specific green color by antioxidants.
- Potassium persulfate was added to 7 mM ABTs solution at a final concentration of 2.4 mM. They reacted in the dark for 12 hours to 16 hours at R/T so as to produce ABTs cations. The resulting ABTs cation was diluted to be used, having an absorbance value of 0.7±0.02. 10 μL the sample was treated with 190 μL ABTs+ working solution and reacted for 6 minutes in a 96-well plate. The absorbance thereof was measured at 732 nm. The radical scavenging activity was calculated from the measured values as follows. BHT was used as a positive control. The antioxidant ability of the sample is determined by the IC50 value in which 50% of ABTs was reduced.
-
Percentage inhibiting activity I(%)=(A control A sample)/A control/×100 - Acontrol: Control (blank sample)
- Acontrol: Sample measurement value
- As shown in Table 1, the results indicate that IC50 values of Sargassum serratifolium ethanol extract and hexane fraction thereof were 17.44±3.1 μg/mL and 14.69±3.4 μg/mL, respectively, and these values were somewhat higher than those of BHT used as a positive control (See Table 1).
- <2-5> Hydroxyl Radical Scavenging
- Hydroxyl radicals (—OH) are the most reactive radicals among oxygen radicals, which occur during aerobic metabolism in the human body. These radicals damage peripheral cells to create collateral living body molecules. A deoxyribose test was performed so as to measure the ability to scavenge hydroxyl radicals. Hydroxyl radicals attack deoxyribose to create small fragments. Some of which are pink when added with TBA (thiobarbituric acid) under an acidic pH environment, so the degree of damage by hydroxyl radicals is measured by absorbance at 532 nm.
- Experimental methods described in Chandini, Ganesan, and Bhaskar (Chandini, S. K., Ganesan, p., and Bhaskar, N. (2008) In vitro antioxidant activities of three selected brown seaweeds of India. Food Chemistry, 107, 707-713) were modified to be used. This reaction used 20 mM phosphate buffer (pH 7.4). Ferric chloride (FeCl3) and EDTA (ethylenediaminetetraacetic acid), respectively, were dissolved as to be 1 mM, and deoxyribose, a reaction substrate, was added to be 2.8 mM, thereby preparing a working solution. 1 ml the sample to be measured was mixed with the working solution, and 0.1 ml ascorbic acid (1 mM) is added to form Fe2+-EDTA mixture which is an oxidized form of ferric chloride (FeCl3) and ethylenediamine tetraacetic acid (EDTA). Then, 0.5 ml of 20 mM hydrogen peroxide (H2O2) was added to form Fe3+-EDTA and HO radical. They were then incubated at 37° C. for 1 hour. After the incubation, 1 ml of 2.8% Trichloroacetic acid (TCA) and 1% TBA, respectively, were added. The mixture was boiled in boiling water at 100° C. for 30 minutes. The absorbance thereof was measured. BHT (2 μg/ml to 25 μg/ml) was used as a positive control.
-
Hydroxy radical scavenging ability(%)=(A control −A sample)/A control×100 - Acontrol: Control (blank sample)
- Acontrol: Sample measurement value
- As shown in Table 1, the results indicate that IC50 values of Sargassum serratifolium ethanol extract and hexane fraction thereof were 1.12±0.15 μg/mL and 1.08±0.19 μg/mL, respectively. These values indicate that the antioxidative activity thereof was showed at a lower concentration compared to BHT used as a positive control (See Table 1).
-
TABLE 1 Antioxidant activity of Sargassum serratifolium ethanol extract and hexane fraction thereof DPPH ABTs OH radical (IC50, μg/ml) (IC50, μg/ml) (IC50, μg/ml) Sargassum serratifolium 11.17 ± 0.42 17.44 ± 3.1 1.12 ± 0.15 Hexane fraction of 9.05 ± 0.21 14.69 ± 3.4 1.08 ± 0.19 Sargassum serratifolium BHT (Control) 11.18 ± 0.15 7.77 ± 0.74 1.675 ± 0.21 - Evaluation of Cytotoxicity of Sargassum serratifolium Ethanol Extract and Compounds Separated Therefrom (Sargahydroquinoic Acid (SHO), Sargachromenol (SCM) and Sargaquinoic Acid (SOA)) of the Present Invention on 661W Photoreceptor Cells
- In this experiment, the cytotoxicity of Sargassum serratifolium ethanol extract and the compounds separated therefrom prepared in Examples 1 and 2 on 661W photoreceptor cells was confirmed. The 661W photoreceptor cells are cell lines established by Dr. Al-Ubaidi. Dr. Al-Ubaidi supplied the cells, which were used in the experiment.
- 661W photoreceptor cells were cultured in 96-wells at a concentration of 3×103 cells/well. Then, they were treated with 1.0 μg/ml Sargassum serratifolium ethanol extract or compounds separated therefrom (sargahydroquinoic acid (SHQ), sargachromenol (SCM), and sargaquinoic acid (SQA)) at a concentration of 1.0 μM and cultured for 24 hours. Then, the medium was replaced with medium containing MTS reagent. Then, they were cultured for 1 hour. Cell viability was measured by measuring the absorbance at 490 nm and comparing the results. The cell viability thereof was analyzed by Celltiter96 Aqueous One solution assay kit (Promega).
- As illustrated in
FIGS. 11 and 12 , the results indicate that no cytotoxicity was observed in the 661W photoreceptor cells in both Sargassum serratifolium ethanol extract (1 μg/ml) and the compound separated therefrom (1 μM). For reference, there was no cytotoxicity of Sargassum serratifolium ethanol extract up to a concentration of 2 μg/ml. There were also no cytotoxicity of sargahydroquinoic acid up to a concentration of 2.5 μM, sargachromenol up to a concentration of 2.5 μM, and sargaquinoic acid up to a concentration of 1.0 μM. - Protective Effect of Sargassum serratifolium Ethanol Extract and Compounds Separated Therefrom (Sargahydroquinoic Acid (SHO), Sargachromenol (SCM) and Sargaquinoic Acid (SOA)) of the Present Invention on 661W Photoreceptor Cells from Oxidative Stress
- <4-1> Effect on the Cell Viability of 661W Cells Under Oxidative Stress
- In order to examine the protective effect of the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention prepared from Examples 1 and 2 on 661W photoreceptor cells, it is examined how the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention effect on the death of 661W photoreceptor cells treated with atRAL.
- In other words, the atRAL is an intermediate metabolite of the visual cycle and is an aldehyde-type compound. The atRAL may induce excessive oxidative stress in cells. Therefore, when 661W photoreceptor cells were treated with the atRAL compound to induce the oxidative stress, the protective effect of the Sargassum serratifolium ethanol extract and the compound separated therefrom of the present invention on 661W photoreceptor cells was examined.
- In detail, 661W photoreceptor cells were cultured in 96-wells at a concentration of 3×103 cells/well and treated with atRAL having a concentration of 1.8 μM (Sigma Aldrich, St. Louis, Mo., USA) for 24 hours. Then, the medium was replaced with medium containing MTS reagent, and they were cultured for 1 hour. The absorbance thereof was measured at 490 nm, and the results were compared to determine cell viability. The cell viability thereof was measured by Celltiter96 Aqueous One solution assay kit (Promega).
- As illustrated in
FIG. 13 , the results indicate that the cell viability of 661W photoreceptor cells was reduced by about 55% in the only atRAL-treated group, whereas the cell viability in the experimental group treated with 0.5 μg/mL Sargassum serratifolium ethanol extract and atRAL was increased by about 25% compared to the experimental group treated with the only atRAL. - Further, the cell viability of 661W photoreceptor cells was more than 90% in the experimental group treated with 0.5 μM of sargahydroquinoic acid (SHQ), sargachromenol (SCM) and sargaquinoic acid (SQA), respectively, so that no significant difference was found between the atRAL-treated group and the untreated group. The results demonstrate that the compounds derived from Sargassum serratifolium of the present invention have a very high protection effect on 661W photoreceptor cells.
- In sum, it was concluded that the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention had the effect of protecting the photoreceptor cells within the range of showing no cytotoxicity.
- <4-2> Inhibitory Effect on Reactive Oxygen Species in 661W Cells Under Oxidative Stress
- In order to check whether the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention prepared from Examples 1 and 2 have the antioxidant activity in 661W photoreceptor cells under oxidative stress, the inhibitory effect of the reactive oxygen species in 661W photoreceptor cells treated with atRAL was observed in this experiment.
- For reference, 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) converts to DCF, which expresses fluorescence in response to oxidative stress in cells. Therefore, the expression of DCF in cells is used as an indicator of the degree of oxidative stress.
- In order to examine the antioxidative effect of the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention, atRAL (1.8 μM) and Sargassum serratifolium ethanol extract (0.5 μg/mL), sargachromenol (0.5 μM), sargahydroquinoic acid (0.5 μM), or sargaquinoic acid (1.0 μM) were added to medium mixed with DCFH-DA (20 μM), and the photoreceptor cells were treated with them and cultured for 30 minutes. Then, the cells were washed with PBS, and the cells were recovered. The cells expressing the fluorescence were measured using flow cytometry.
- As illustrated in
FIG. 14 , the results demonstrate that the cells treated with atRAL only had a fluorescence expression level having about 80% higher than that of the control group. In the group treated with atRAL and Sargassum serratifolium ethanol extract 0.5 μg/mL, the fluorescence expression level was reduced by about 75% compared to the group treated with atRAL only. In the groups treated with atRAL and sargachromenol (0.5 μM), sargahydroquinoic acid (0.5 μM), or sargaquinoic acid (1.0 μM), the fluorescence expression levels were reduced by 76%, 77%, and 73%, respectively, and there was no difference from the control group untreated with atRAL. - Therefore, the Sargassum serratifolium ethanol extract and the compound separated therefrom were found to effectively inhibit atRAL-induced oxidative stress, thereby protecting photoreceptors.
- <4-3> Inhibitory Effect on Malondialdehyde in 661W Cells Under Oxidative Stress
- In order to check whether the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention prepared in Examples 1 and 2 have antioxidant activity in 661W photoreceptor cells under oxidative stress, the inhibitory level of malondialdehyde (MDA) production in 661W photoreceptor cells treated with atRAL was observed in this experiment. For reference, the malondialdehyde (MDA) is the result of lipid peroxidation by excessive oxidative stress in cells, and thus the amount of MDA in cells is a factor to measure the degree of oxidative stress.
- In detail, samples of each of Sargassum serratifolium ethanol extract and the compounds separated therefrom were mixed with a specific amount of atRAL (1.8 μM) and Sargassum serratifolium ethanol extract (0.5 μg/mL), sargachromenol (0.5 μM), sargahydroquinoic acid (0.5 μM), or sargaquinoic acid (1.0 μM). The photoreceptor cells were treated with mixtures thereof. Then, they were cultured for 2 hours. The cells were then washed with PBS and the intracellular proteins were recovered. The number of proteins denatured by the lipid peroxides in cells was analyzed by protein immunoassay using MDA immunoblot kit (Cell biolabs).
- As illustrated in
FIG. 15 , the results indicate that the cells treated with atRAL only showed an increase in expression level of protein denatured by MDA compared with the control, whereas the group treated with atRAL and Sargassum serratifolium ethanol extract having 0.5 μg/mL of the present invention has decreased expression level of MDA peroxidase protein compared with the group treated with atRAL only. The expression level of MDA peroxidase protein was similarly decreased in the experimental groups treated with atRAL and the compounds separated from Sargassum serratifolium ethanol extract, respectively. - Therefore, it is determined that the Sargassum serratifolium ethanol extract and the compound separated therefrom effectively inhibit atRAL-induced oxidative stress so that the photoreceptors are protected by inhibiting peroxidation of cell membrane lipid component.
- The present invention is characterized by providing an antioxidant composition including a Sargassum serratifolium extract or a fraction thereof in an active ingredient.
- “Sargassum serratifolium” of the present invention is a marine algae in Sargassaceae family of phaeophyta division, which is distributed in the south coast and Jeju region in Korea. The plant is 1 m to 4 m and its root diameter is 4 cm to 5 cm, which has cone-shape. It is like rubber and has a ring.
- Until now, no study has been reported that such Sargassum serratifolium is related to the antioxidative activity.
- The present inventors have selected the Sargassum belonging to Sargassum family as a substance of medicines, food, and cosmetic composition and produced extracts thereof. It is confirmed that Sargassum serratifolium among various kinds of Sargassum has an excellent antioxidative activity.
- In detail, in order to evaluate the antioxidative activity of the Sargassum serratifolium ethanol extract and the hexane fraction separated therefrom, the present inventor measured the amount of nitric oxide produced in the following Experimental Example <2-1>. The results indicate that the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently. The EC50 values of the ethanol extract and the hexane fraction were 0.72 μg/mL and 0.68 μg/mL, respectively (See
FIG. 9 ). - Further, in the following experimental example <2-2>, intracellular reactive oxygen species were measured. The results indicate that the production of reactive oxygen species induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently. The IC50 values of the ethanol extract and the hexane fraction were 1.4±0.11 μg/mL and 1.3±0.12 μg/mL, respectively (See
FIG. 10 ). - Further, DPPH radical scavenging activity, ABTs cation scavenging activity, and hydroxyl radical (—OH) scavenging activity were measured in the following Experimental Examples <2-3> to <2-5>, respectively. The results demonstrate that the Sargassum serratifolium ethanol extract and the hexane fraction thereof of the present invention showed 50% scavenging activity (IC50) in the concentration range of 1 μg/ml to 20 μg/ml. These values show a higher antioxidative activity compared with BHT as a positive control group (See Table 1).
- The results objectively demonstrate that the Sargassum serratifolium extract and the fraction thereof of the present invention show an excellent antioxidative activity, and it is supported by the experiments.
- Therefore, the composition of the present invention, including Sargassum serratifolium extract and fraction thereof as an active ingredient may be useful as a functional material showing an antioxidative activity.
- The Sargassum serratifolium extract according to the present invention may be used as one obtained by extracting and separating from nature using an extraction and separation method known in the art. The “extract” defined in the present invention may be extracted from Sargassum serratifolium using an appropriate solvent. It includes, for example, a crude extract, polar solvent extract or non-polar solvent extract of Sargassum serratifolium
- Any pharmaceutically acceptable organic solvent may be used as an appropriate solvent for extracting the extract from the Sargassum serratifolium. Water or an organic solvent may be used. Various solvents such as purified water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, and butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination, but the solvent may not be limited thereto. Preferably, ethanol may be used, and more preferably, 95% ethanol may be used.
- The extraction method may use any one selected from methods including hot water extraction, chilling extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, pressing, and the like. Further, the desired extract may additionally perform a general fraction process and be purified using a general purification method. The method of preparing the Sargassum serratifolium extract of the present invention is not limited and may use any known method.
- For example, in the Sargassum serratifolium extract included in the composition of the present invention, a primary extract extracted by the hot water extraction or solvent extraction may be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying, or spray-drying. Further, the primary extract may obtain additionally purified fractions using various types of chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, and the like.
- Accordingly, in the present invention, the Sargassum serratifolium extract is a concept including all of the extracts, fractioned and purified materials, their dilutions, concentrates, or dried materials which are obtained in each step of extraction, fraction, or purification.
- The method of preparing the Sargassum serratifolium extract according to the exemplary embodiment of the present invention is described below in more detail.
- The dried Sargassum serratifolium is powdered. Then, 95% ethanol is used as an extraction solvent to perform the extraction using the reflux cooling extraction, followed by filtration and concentration.
- This Sargassum serratifolium ethanol extract can be further fractionated using an n-hexane solvent. For example, the Sargassum serratifolium ethanol extract is dissolved in a mixed solvent of water and ethanol in a volume ratio of 9:1, and then equilibrated by adding the same amount of n-hexane. Then, the upper n-hexane soluble portion may be filtered and concentrated to produce the hexane fraction of Sargassum serratifolium ethanol extract.
- Accordingly, the composition of the present invention corresponds to an antioxidant composition including the Sargassum serratifolium extract or the fraction thereof as an active ingredient.
- In the present invention, “antioxidant composition” refers to a substance that prevents oxidation by inhibiting or eliminating active oxygen having an unstable state of oxygen.
- The antioxidant composition of the present invention may be used for various objects and purposes requiring antioxidative activity. Specifically, the antioxidant composition may be used as a functional material which provides the antioxidative activity products which are applicable to various industrial fields such as pharmaceuticals, cosmetics, foods, and animal feed. It can also be used as a substance such as medicine preservative, a cosmetic preservative, a food preservative, a pharmaceutical additive, a cosmetic additive, a food additive, and a feed additive.
- Hereinafter, pharmaceuticals, cosmetics, food, and animal feeds to which the antioxidant composition of the present invention can be applied are described in detail.
- The antioxidant composition of the present invention may be a pharmaceutical composition for preventing or treating oxidation-related diseases, including a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- The pharmaceutical composition of the present invention may be prepared by using pharmaceutically-suitable and physiologically-acceptable additives in addition to the active ingredient, and the additives may be an excipient, a disintegrant, a sweetener, a binder, a coating agent, an inflating agent, a glidant, a lubricant, a flavoring agent, and the like.
- The pharmaceutical composition may preferably be formulated as a pharmaceutical composition by additionally including at least one of pharmaceutically acceptable carriers in addition to the active ingredient for administration.
- A formulation of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppository, liquid, syrup, juice, a suspension, an emulsion, an ointment, an injectable liquid formulation, and the like.
- For example, an active ingredient may be combined with an oral and non-toxic pharmaceutical acceptable inert carrier, such as ethanol, glycerol, water in order to formulate as a type of tablets or capsules. In addition, if it is necessary or required, a suitable binding agent, a lubricant, a disintegrant and a coloring agent may be also included as a mixture. The suitable binding agent includes starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweetening agents, natural or synthetic gums such as acacia, tragacanth, or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like, but is not limited thereto. The disintegrant includes starch, methylcellulose, agar, bentonite, xanthan gum, and the like, but is not limited thereto. A pharmaceutically acceptable carrier for a composition formulated as a liquid solution may be suitable for a sterilization and a body, and may be saline solution, sterilized water, Ringer solution, butter saline solution, albumin injection solution, dextrose solution, malto dextrin solution, glycerol, ethanol, and the mixture of at least one thereof, and other general additives, such as antioxidants, a buffering solution, and bacteriostat may be added as needed. In addition, tablets, granules, capsules, a pill, a dosage form for injecting, such as an aqueous solution, suspension, and an emulsion may be formulated by additionally adding a diluent, a dispersing agent, a surfactant, a binding agent, and a lubricant. Furthermore, it may be preferably formulated depending on each disease or each component using the method as disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton Pa. as a suitable method in the related art.
- In an aspect of the present invention, the Sargassum serratifolium extract or fraction thereof of the present invention may be included in 0.00001% by weight to 40% by weight with respect to the total weight of the composition.
- In another aspect of the present invention, the Sargassum serratifolium extract or fraction thereof of the present invention may be included at a concentration of 0.1 μg/ml to 10000 μg/ml with respect to the composition.
- The oxidation-related diseases in which the pharmaceutical composition of the present invention may have a therapeutic effect may include nasitis, asthma, acute pain, chronic pain, paradentitis, gingivitis, inflammatory bowel disease, gout, myocardial infarction, arteriosclerosis, congestive heart failure, hypertension, angina pectoris, stomach ulcer, Alzheimer's disease, cerebral infarction, Down's syndrome, multiple sclerosis, obesity, diabetes, dementia, depression, schizophrenia, tuberculosis, sleep disorder, sepsis, a burn, pancreatitis, and eye diseases, but is not limited thereto.
- The composition of the present invention may also be a food composition. Such a food composition may include various flavors or natural carbohydrates as well as the Sargassum serratifolium extract or fraction thereof as an active ingredient like conventional food compositions.
- Examples of the natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as general sugar including dextrin and cyclodextrin and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (thaumatin), stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (e.g., saccharin, aspartame, etc.) may be advantageously used as a flavor.
- The food composition of the present invention may be formulated in the same method as the pharmaceutical composition. So, the food composition may be used as a functional food or in by adding to various foods. Examples of foods to which the composition of the present invention may be added include beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- Further, the food composition may include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like as well as the Sargassum serratifolium extract and fraction thereof as an active ingredient. In addition, the food composition of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks, and vegetable drinks.
- Such a Sargassum serratifolium extract or a fraction thereof, which is the active ingredient of the present invention, is a natural material and has few side effects, unlike chemicals, so that it can be safely used for long-term use for the purpose of imparting antioxidant function.
- The present invention may include a health functional food for preventing or alleviating oxidation-related diseases, in which the health functional food may include a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
- The health functional food of the present invention may be produced and processed in the form of tablets, capsules, powders, granules, liquids, and pills for the purpose of preventing or alleviating oxidation-related diseases.
- The term “health functional food” in the present invention refers to foods produced or processed using raw materials or components that have useful functionality in the human body according to the health functional food law or means that the food is ingested for the purpose of obtaining a beneficial effect for health use such as controlling nutrients or physiological action for the structure and function of the human body.
- The health functional food of the present invention may include common food additives. The conformity of the “food additive” is determined, as long as there are no other regulations, in consideration with the standard and criteria of the corresponding item according to the general rule of the food additives codex and general tests approved by the Korean Ministry of Food and Drug Safety.
- The items listed on the “food additives codex” include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon color, licorice extract, crystalline cellulose, kaoliang color, and guar gum; and mixed preparations such as L-glutamic acid sodium preparations, alkalis additives for noodle, preservative preparations, tar color preparations.
- For example, in order to produce a health functional food in a tablet form, a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention, excipients, binders, disintegrants, and other additives can be granulated using a conventional method, and then compression molding process is performed with lubricants. Alternatively, the mixture can be directly subjected to the compression molding process. In addition, when needed, the health functional food in a tablet form may include sweetening agents.
- Among health functional foods in a capsule form, a hard capsule formulation can be produced by filling a conventional hard capsule with a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention and additives such as excipients; and a soft capsule formulation can be produced by filling a capsule support of gelatin with a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention and additives such as excipients. When needed, the soft capsule formulation can include plasticizers, such as glycerin or sorbitol, coloring agents, and preservatives.
- A health functional food in a pill form can be produced by molding a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods. When needed, the health functional food in a pill form can be coated with white sugar or other coating materials, or the surface thereof can be coated with starch, talc, or other materials.
- A health functional food in a granule form can be produced by granulating a mixture of the Sargassum serratifolium extract or fraction thereof as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods. When needed, the health functional food in a granule form can include flavoring agents and sweetening agents.
- The health functional food containing the Sargassum serratifolium extract or the fraction thereof as an active ingredient of the present invention has been experimentally proved to have excellent antioxidative effects as shown in the following examples, and thus it is effective for preventing or alleviating oxidation-related diseases.
- The health functional food may be beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- The composition of the present invention may be a cosmetic composition as well as a pharmaceutical composition or a food composition.
- The Sargassum serratifolium extract or fraction thereof of the present invention has an excellent scavenging activity against the most reactive hydroxyl radicals among the reactive oxygen species as well as scavenging activity against nitric oxide so that it has an excellent antioxidative activity. Thus, the composition including the Sargassum serratifolium extract or fraction thereof may be useful as a cosmetic composition because it is effective for skin protection and skin treatment from reactive oxygen species (ROS) that induce damage to human cells to accelerate aging and mediate oxidation-related diseases.
- When the composition of the present invention is prepared as a cosmetic composition, the composition of the present invention may include not only the Sargassum serratifolium extract or fraction thereof, but also compositions commonly used in cosmetic compositions such as commonly used supplements such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.
- In addition, the composition of the present invention may be used in combination with the above-mentioned Sargassum serratifolium extract or fraction thereof and conventionally used antioxidants to the extent that it does not adversely affect the skin protecting effect by reacting with the Sargassum serratifolium extract or fraction thereof.
- Examples of products added to the cosmetic composition of the present invention may include cosmetics such as astringents, toners, nutritional lotions, various creams, essences, packs and foundations, cleansers, facial cleaning agents, soaps, treatment agents, and beauty liquids.
- Specific formulations of the cosmetic compositions of the present invention include skin lotions, skin softeners, skin toners, astringents, lotions, milky lotions, moisturizing lotions, nutritional lotions, massage creams, nutritional creams, moisturizing creams, hand creams, essences, nutritional essences, packs, soap, shampoo, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, milky liquid, lipsticks, makeup base, foundations, press powders, loose powders, eyeshadow, and the like.
- According to a preferred embodiment of the present invention, the content of the Sargassum serratifolium extract or fraction thereof of the present invention is 0.00001% by weight to 40% by weight, preferably 0.1% by weight to 20% by weight, more preferably 1.0% by weight to 20% by weight with respect to the total weight of the composition. When the content of the Sargassum serratifolium extract or fraction thereof is less than 0.00001% by weight, the antioxidative effect caused by the extract and the fraction thereof is significantly reduced. When the content is more than 40% by weight, skin irritation may be caused and a problem may occur in the formulation thereof.
- Meanwhile, the cosmetic composition according to the present invention can be formulated in which the Sargassum serratifolium extract or fraction thereof is contained inside the nanoliposome, resulting in its stabilization. When the extract (or fraction thereof) is contained inside the nanoliposome, the composition of the extract (or fraction thereof) is stabilized. Thus, when formulated, problems such as precipitation formation, discoloration, and changing scent may be solved. Further, the solubility and transdermal absorption rate thereof may be improved. Therefore, the expected efficacy from the extract (or fraction thereof) may be maximized.
- In the present invention, nanoliposomes are liposomes having a typical liposome shape and refer to liposome having an average particle diameter of 10 nm to 500 nm. According to a preferred embodiment of the present invention, the average particle diameter of the nanoliposome is 50 nm to 300 nm. When the average particle diameter of the nanoliposome exceeds 300 nm, among technological effects to be achieved in the present invention, the improvement of the skin penetration thereof and the improvement of the formulation stability thereof are very weak.
- The nanoliposomes used to stabilize the extract (or fraction thereof) according to the present invention may be prepared using a mixture including a polyol, an oily composition, a surfactant, a phospholipid, a fatty acid, and water.
- The polyol used in the nanoliposome of the present invention is not particularly limited, but preferably includes at least one selected from the group consisting of propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isopropylene glycol, pentylene glycol, erythritol, xylitol, sorbitol, and mixtures thereof. The content thereof is 10% by weight to 80% by weight, preferably 30% by weight to 70% by weight, with respect to the total weight of the nanoliposome.
- The oil composition used in the preparation of the nanoliposome of the present invention may include a variety of oils known in the art and, but include preferably hydrocarbon-based oil such as hexadecane and paraffin oil, an ester-based synthetic oil, silicone oil such as dimethicone-based oil and cyclomethicone-based oil, animal-vegetable oil such as sunflower oil, corn oil, soybean oil, avocado oil, sesame oil and fish oil, ethoxylated alkyl ether-based oil, propoxylated alkyl ether-based oil, sphingoid lipid such as phytosphingosine, sphingosine and sphinganine, cerebroside cholesterol, sitosterol cholesteryl sulfate, cetostearyl sulfate, C10-40 fatty alcohols and mixtures thereof. The amount thereof may be 1.0% by weight to 30.0% by weight, and preferably 3.0% by weight to 20.0% by weight with respect to the total weight of the nanoliposome.
- Any surfactant known in the art may be used as the surfactant used in the preparation of the nanoliposome of the present invention. For example, anionic surfactants, cationic surfactants, amphoteric surfactants and nonionic surfactants may be used. Preferably, anionic surfactants and nonionic surfactants may be used. Specific examples of anionic surfactants include alkyl acyl glutamate, alkyl phosphates, alkyl lactylate, dialkyl phosphate and trialkyl phosphate. Specific examples of nonionic surfactants include alkoxylated alkyl ether, alkoxylated alkyl ester, alkyl polyglycoside, polyglyceryl ester and sugar ester. Particularly, the preferred surfactant is polysorbate-based compound belonging to nonionic surfactants. The amount thereof may be 0.1% by weight to 10% by weight, preferably 0.5% by weight to 5.0% by weight with respect to the total weight of the nanoliposome.
- Another composition used in the preparation of the nanoliposome of the present invention is phospholipids which are amphiphilic lipids. The phospholipids include natural phospholipids (for example, egg yolk lecithin or soy lecithin, sphingomyelin) and synthetic phospholipids (for example, dipalmitoyl phosphatidylcholine or hydrogenated lecithin). Preferably, the phospholipid is lecithin. In particular, unsaturated lecithin or saturated lecithin derived from natural origin extracted from soybean or egg yolk is preferred. Typically, the amount of phosphatidylcholine in the naturally occurring lecithin is 23% to 95%, and the amount of phosphatidyl ethanolamine is 20% or less. In the preparation of the nanoliposome of the present invention, the amount of phospholipid to be used is 0.5% by weight to 20.0% by weight, preferably 2.0% by weight to 8.0% by weight with respect to the total weight of the nanoliposome.
- The fatty acid used in the preparation of the nanoliposome of the present invention includes higher fatty acids, preferably saturated or unsaturated fatty acids of C12-22 alkyl chains, such as lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid. The amount thereof may be 0.05% by weight to 3.0% by weight, preferably 0.1% by weight to 1.0% by weight with respect to the total weight of the nanoliposome.
- The water used in the preparation of the nanoliposome of the present invention is generally deionized distilled water. The amount thereof may be 5.0% by weight to 40% by weight with respect to the total weight of the nanoliposome.
- The nanoliposome may be prepared by a variety of methods known in the art, but the most preferred method is carried out by applying a mixture including the components to a high-pressure homogenizer. The nanoliposome may be prepared by a high-pressure homogenizer under various conditions (for example, pressure, number of times, etc.) depending on the desired particle size. Preferably, the nanoliposome may be prepared in which the mixture passes through a high-
pressure homogenizer 1 to 5 times at a pressure of 600 bar to 1200 bar. - The cosmetic composition according to the present invention may contain the Sargassum serratifolium extract or fraction thereof having 0.1% by weight to 20.0% by weight with respect to the weight of the nanoliposome and more preferably 1.0% by weight to 10.0% by weight for stabilizing the formulation.
- In an aspect of the present invention, the Sargassum serratifolium extract or fraction thereof may be included in the cosmetic composition at a concentration of 0.1 μg/ml to 10000 μμg/ml.
- Further, the composition of the present invention may be a feed composition or a feed additive which may impart the antioxidant functionality thereto.
- The feed composition according to the present invention may contain the Sargassum serratifolium extract or fraction thereof in an amount of 0.1% by weight to 50% by weight, more preferably 1% by weight to 20% by weight with respect to the total weight of the composition, but is not limited thereto. Meanwhile, when used as a feed additive, the Sargassum serratifolium extract or fraction thereof can be mixed and used in the feed composition.
- Further, the present invention provides an antioxidation or anti-aging method including administering a Sargassum serratifolium extract or a compound separated therefrom to an individual.
- The antioxidation or anti-aging method of the present invention includes administering a Sargassum serratifolium extract or a compound separated therefrom of the present invention to an individual in a therapeutically effective amount. The specific therapeutically effective amount for any particular individual may vary depending on various factors well known in the medical art and other factors including the kind and degree of the response to be achieved, whether other agents are used therewith or not, specific composition, the patient's age, body weight, health conditions, gender, and diet, the time and route of administration, the secretion rate of the composition, the time period of therapy, other drugs used in combination or coincidentally with the specific composition. Therefore, the effective amount of the composition suitable for the purpose of the present invention is preferably determined in consideration of the matters as described above.
- Any mammal is applicable to the individual. The mammal includes livestock such as cows, pigs, sheep, horses, dogs and cats as well as humans and primates.
- Further, the present invention is characterized by providing an antioxidant composition for preventing or alleviating eye diseases, which includes the Sargassum serratifolium extract or a fraction thereof as an active ingredient.
- Until now, the Sargassum serratifolium has not been reported to have the preventive, ameliorative and therapeutic effects on eye diseases.
- The present inventors have confirmed through experiments that the Sargassum serratifolium has superior antioxidative activity among the various types of Sargassum so that it is effective in preventing, alleviating, and treating eye diseases associated with oxidative stress.
- In detail, in order to examine preventive, ameliorative and therapeutic effects of the Sargassum serratifolium extract and compound separated therefrom (SHQ, SCM and SQA) on eye diseases, the present inventor investigated their effects on the survival rate of oxidative stressed 661W cells (mouse-derived photoreceptor cells) in the following Experimental Example 4-1. The results indicate that the group treated with the only atRAL, which is an oxidative stress inducer, showed the decreased survival rate of 661W photoreceptor cells by about 55%, on the other hand, the group treated with atRAL and the Sargassum serratifolium ethanol extract together exhibited the increased survival rate of 661W photoreceptor cells by about 25% compared with the group treated with the only atRAL. Further, the group treated with atRAL and SHQ, SCM and SQA, respectively, showed more than 90% of the survival rate of 661W photoreceptor cells, indicating no significant difference compared to the group non-treated with atRAL. The results demonstrate that the Sargassum serratifolium ethanol extract and the compound separated therefrom (SHQ, SCM and SQA) of the present invention have a very high protective effect on the 661W photoreceptor cells within the range of no cytotoxicity (See
FIG. 13 ). - Further, in the following Experimental Example 4-2, the effect of inhibiting reactive oxygen species was examined in 661W photoreceptor cells treated with atRAL, which is an oxidative stress inducer. The results indicate that the group treated with atRAL and the Sargassum serratifolium ethanol extract together exhibited the deceased fluorescence expression level by about 75% compared with the group treated with the only atRAL. Further, the group treated with atRAL and SHQ, SCM and SQA, respectively, showed the decreased fluorescence expression level by about 76%, 77% and 73%, indicating no significant difference compared to the group non-treated with atRAL. Therefore, it was confirmed that the Sargassum serratifolium ethanol extract and the compound separated therefrom (SHQ, SCM and SQA) of the present invention effectively inhibit the oxidative stress induced by atRAL, thereby protecting photoreceptor cells (See
FIG. 14 ). - Further, the inhibitory effect on malondialdehyde (MDA) in 661W cells under the oxidative stress was measured in the following Experimental Example 4-3. The results show that the expression level of protein denatured by MDA increased in the cells treated with the only atRAL. Meanwhile the expression level of MDA peroxidase protein in the experimental group treated with atRAL and the Sargassum serratifolium ethanol extract of the present invention together decreased compared to the group with the only atRAL. In addition, it was confirmed that the expression level of MDA peroxidase protein was effectively reduced in the group treated with atRAL and SHQ, SCM and SQA, respectively. Therefore, it was determined that the Sargassum serratifolium ethanol extract and the compound separated therefrom effectively inhibit the oxidative stress, thereby resulting in the inhibition of peroxidation of cell membrane lipid component so as to protect photoreceptor cells (See
FIG. 15 ). - The results demonstrate objectively through experiments that the Sargassum serratifolium extract and compound separated therefrom of the present invention (SHQ, SCM and SQA) are excellent effective in preventing, alleviating, and treating eye diseases associated with oxidative stress.
- Therefore, the composition of the present invention, including a Sargassum serratifolium extract and a compound separated therefrom as an active ingredient may be useful as a functional material for preventing, alleviating, and treating eye diseases associated with oxidative stress.
- The Sargassum serratifolium extract according to the present invention may be used as one obtained by extracting and separating from nature using an extraction and separation method known in the art. The “extract” defined in the present invention may be extracted from Sargassum serratifolium using an appropriate solvent. It includes, for example, a crude extract, polar solvent extract or non-polar solvent extract of the Sargassum serratifolium.
- Any pharmaceutically acceptable organic solvent may be used as an appropriate solvent for extracting the extract from the Sargassum serratifolium. Water or an organic solvent may be used. Various solvents such as purified water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol and butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination, but the solvent may not be limited thereto. Preferably, ethanol may be used, and more preferably, 95% ethanol may be used.
- The extraction method may use any one selected from methods including hot water extraction, chilling extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, pressing, and the like. Further, the desired extract may additionally perform a general fraction process and be purified using a general purification method. The method of preparing the Sargassum serratifolium extract of the present invention is not limited and may use any known method.
- For example, in the Sargassum serratifolium extract included in the composition of the present invention, a primary extract extracted by the hot water extraction or solvent extraction may be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying or spray-drying. Further, the primary extract may obtain additionally purified fractions using various types of chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography.
- Accordingly, in the present invention, the Sargassum serratifolium extract is a concept including all of the extracts, fractioned and purified materials, their dilutions, concentrates, or dried materials which are obtained in each step of extraction, fraction, or purification.
- The method of preparing the Sargassum serratifolium extract according to the exemplary embodiment of the present invention is described below in more detail.
- The dried Sargassum serratifolium is powdered. Then, 95% ethanol is used as an extraction solvent to perform the extraction using the reflux cooling extraction, followed by filtration and concentration.
- Further, SHQ, SCM and SQA compounds may be separated from the Sargassum serratifolium ethanol extract of the present invention through step-by-step processes (See Example 2).
- Accordingly, the composition of the present invention corresponds to a pharmaceutical composition for preventing or treating eye diseases, which includes the Sargassum serratifolium extract or compound separated therefrom as an active ingredient.
- In an aspect of the present invention, the Sargassum serratifolium extract may be a Sargassum serratifolium ethanol extract extracted with ethanol solvent, and the compound may be sargahydroquinoic acid (SHQ), sargaquinoic acid (SQA) or sagachromenol (SCM).
- The pharmaceutical composition of the present invention may be prepared by using pharmaceutically-suitable and physiologically-acceptable additives in addition to the active ingredient, and the additives may be an excipient, a disintegrant, a sweetener, a binder, a coating agent, an inflating agent, a glidant, a lubricant, a flavoring agent, and the like.
- The pharmaceutical composition may preferably be formulated as a pharmaceutical composition by additionally including at least one of pharmaceutically acceptable carriers in addition to the active ingredient for administration.
- A formulation of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppository, liquid, syrup, juice, a suspension, an emulsion, an ointment, an injectable liquid formulation, and the like.
- For example, an active ingredient may be combined with an oral and non-toxic pharmaceutical acceptable inert carrier, such as ethanol, glycerol, and water in order to formulate as a type of tablets or capsules. In addition, if it is necessary or required, a suitable binding agent, a lubricant, a disintegrant and a coloring agent may be also included in a mixture. The suitable binding agent includes starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweetening agents, natural or synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like, but is not limited thereto. The disintegrant includes starch, methylcellulose, agar, bentonite, xanthan gum, and the like, but is not limited thereto. A pharmaceutically acceptable carrier for a composition formulated as a liquid solution may be suitable for a sterilization and a body, and may be saline solution, sterilized water, Ringer solution, butter saline solution, albumin injection solution, dextrose solution, malto dextrin solution, glycerol, ethanol, and the mixture of at least one thereof, and other general additives, such as antioxidants, a buffering solution, and bacteriostat may be added as needed. In addition, tablets, granules, capsules, a pill, a dosage form for injecting, such as an aqueous solution, suspension, and an emulsion may be formulated by additionally adding a diluent, a dispersing agent, a surfactant, a binding agent, and a lubricant. Furthermore, it may be preferably formulated depending on each disease or each component using the method as disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton Pa. as a suitable method in the related art.
- In an aspect of the present invention, the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) of the present invention may be included in 0.00001% by weight to 40% by weight with respect to the total weight of the composition.
- In another aspect of the present invention, the Sargassum serratifolium extract or compound separated therefrom of the present invention may be included at a concentration of 0.1 μg/ml to 10000 μg/ml with respect to the composition, and the compound separated from the Sargassum serratifolium extract (SHQ, SCM, and SQA) may be included at a concentration of 0.1 μg/ml to 10000 μg/ml with respect to the food composition.
- The eye diseases for which the pharmaceutical composition of the present invention has therapeutic effects include age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, cystoid macular edema, and the like, but are not limited thereto. In particular, the Sargassum serratifolium extract or compounds separated therefrom (SHQ, SCM, and SQA) of the present invention has the effect of protecting photoreceptor cells through an excellent antioxidative activity so that it may be more effective in treating the oxidative stress-related eye disease among eye diseases.
- For reference, the oxidative stress plays a critical role in eye tissue and eye disease. The retina of the eye is the tissue with the fastest metabolic rate in the human body, thereby creating a tremendous amount of oxidative stress. Furthermore, when the eye is exposed to high-energy ultraviolet rays, the reactive oxygen species having high reactivity is generated in a significant amount, resulting in fatal eye damage.
- The age-related macular degeneration (hereinafter, referred as to “AMD”) is the most active subject among studies about eye diseases. The several causes of the disease include the production of reactive oxygen derivatives due to excessive oxygen use, accumulation of lipofuscin-retinoid derivatives (bisretinylethanolamine (A2E)), and oxidation by light, but the specific mechanism and treatment methods are not yet known (Zarbin, 2004, Arch Ophthalmol 122, 598-614; Kasahara et al., 2005, Invest Ophthalmol Vis Sci 46, 3426-3434).
- Further, the recent research conducted by the department of ophthalmology of St. Mary's Hospital in Korea has revealed that hydrogen peroxide (H2O2) in the body induces destruction of the retinal pigment epithelium, resulting in macular degeneration.
- Therefore, the material capable of inhibiting or alleviating oxidative stress in the eye tissues and cells may be effectively used for preventing or treating various eye diseases (especially, macular degeneration) caused by the oxidative stress.
- Accordingly, the composition of the present invention includes the Sargassum serratifolium extract or compounds separated therefrom (SHQ, SCM and SQA) as an active ingredient. The active ingredient has the effect of protecting photoreceptor cells through an excellent antioxidative activity so that it may be useful for a pharmaceutical composition for preventing or treating eye diseases caused by the oxidative stress.
- Further, the present invention provides a method of treating an eye disease, including administering a Sargassum serratifolium extract or a compound separated therefrom to an individual.
- The method of treating an eye disease of the present invention includes administering a Sargassum serratifolium extract or a compound separated therefrom of the present invention to an individual in a therapeutically effective amount. The specific therapeutically effective amount for any particular individual may vary depending on various factors well known in the medical art and other factors including the kind and degree of the response to be achieved, whether other agents are used therewith or not, specific composition, the patient's age, body weight, health conditions, gender, and diet, the time and route of administration, the secretion rate of the composition, the time period of therapy, and other drugs used in combination or coincidentally with the specific composition. Therefore, the effective amount of the composition suitable for the purpose of the present invention is preferably determined in consideration of the matters as described above.
- Any mammal is applicable to the individual. The mammal includes livestock such as cows, pigs, sheep, horses, dogs, and cats as well as humans and primates.
- Further, the present invention provides a food composition for preventing or alleviating eye diseases, which includes a Sargassum serratifolium extract or a fraction thereof in an active ingredient.
- In an aspect of the present invention, the Sargassum serratifolium extract may be a Sargassum serratifolium ethanol extract extracted with ethanol solvent, and the compound may be sargahydroquinoic acid (SHQ), sargaquinoic acid (SQA), or sagachromenol (SCM).
- Such a food composition may include various flavors or natural carbohydrates as well as the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient like conventional food compositions.
- Examples of the natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as general sugar including dextrin and cyclodextrin and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavors (thaumatin), stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavors (e.g., saccharin, aspartame, etc.) may be advantageously used as a flavor.
- The food composition of the present invention may be formulated in the same method as the pharmaceutical composition. So, the food composition may be used as a functional food or in by adding to various foods. Examples of foods to which the composition of the present invention may be added include beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- Further, the food composition may include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like as well as the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM, and SQA) as an active ingredient. In addition, the food composition of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
- The eye diseases for which the food composition of the present invention has alleviative effects may be oxidative stress-related eye diseases, which include, for example, age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, cystoid macular edema, and the like, but are not limited thereto.
- In an aspect of the present invention, the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) of the present invention may be included in 0.00001% by weight to 40% by weight with respect to the total weight of the food composition.
- In another aspect of the present invention, the Sargassum serratifolium extract of the present invention may be included at a concentration of 0.1 μg/ml to 10000 μg/ml with respect to the food composition, and the compound separated from the Sargassum serratifolium extract (SHQ, SCM and SQA) may be included at a concentration of 0.1 μg/ml to 10000 μg/ml with respect to the food composition.
- Such a Sargassum serratifolium extract or a compound separated therefrom (SHQ, SCM, and SQA), which is the active ingredient of the present invention, is derived from a natural material and has few side effects unlike chemicals, so that it can be safely used for long-term use for the purpose of imparting functionality of preventing or alleviating oxidative stress-related diseases.
- Further, the present invention may be a health functional food for preventing or alleviating eye diseases, which includes a Sargassum serratifolium extract or a fraction thereof in an active ingredient.
- In an aspect of the present invention, the Sargassum serratifolium extract may be a Sargassum serratifolium ethanol extract extracted with ethanol solvent, and the compound may be sargahydroquinoic acid (SHQ), sargaquinoic acid (SQA), or sagachromenol (SCM).
- In another aspect of the present invention, the eye disease may be oxidative stress-related eye diseases, which include, for example, age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopia degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, cystoid macular edema, and the like, but is not limited thereto.
- The health functional food of the present invention may be produced and processed in the form of tablets, capsules, powders, granules, liquids, and pills for the purpose of preventing or alleviating eye diseases.
- The term “health functional food” in the present invention refers to foods produced or processed using raw materials or components that have useful functionality in the human body according to the health functional food law or means that the food is ingested for the purpose of obtaining a beneficial effect for health use such as controlling nutrients or physiological action for the structure and function of the human body.
- The health functional food of the present invention may include common food additives. The conformity of the “food additive” is determined, as long as there are no other regulations, in consideration with the standard and criteria of the corresponding item according to the general rule of the food additives codex and general tests approved by the Korean Ministry of Food and Drug Safety.
- The items listed on the “food additives codex” include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon color, licorice extract, crystalline cellulose, kaoliang color and guar gum; and mixed preparations such as L-glutamic acid sodium preparations, alkalis additives for noodle, preservative preparations, tar color preparations.
- For example, in order to produce a health functional food in a tablet form, a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention, excipients, binders, disintegrants, and other additives can be granulated using a conventional method, and then compression molding process is performed with lubricants. Alternatively, the mixture can be directly subjected to the compression molding process. In addition, when needed, the health functional food in a tablet form may include sweetening agents.
- Among health functional foods in a capsule form, a hard capsule formulation can be produced by filling a conventional hard capsule with a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention and additives such as excipients; and a soft capsule formulation can be produced by filling a capsule support of gelatin with a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention and additives such as excipients. When needed, the soft capsule formulation can include plasticizers such as glycerin or sorbitol, coloring agents, and preservatives.
- A health functional food in a pill form can be produced by molding a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods. When needed, the health functional food in a pill form can be coated with white sugar or other coating materials, or the surface thereof can be coated with starch, talc, or other materials.
- A health functional food in a granule form can be produced by granulating a mixture of the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention, excipients, binders, and disintegrants using well-known methods. When needed, the health functional food in a granule form can include flavoring agents and sweetening agents.
- The health functional food containing the Sargassum serratifolium extract or compound separated therefrom (SHQ, SCM and SQA) as an active ingredient of the present invention has been experimentally proved to have the effect of protecting photoreceptor cells through the excellent antioxidative effects as shown in the following examples, and thus it is effective for preventing or alleviating oxidative stress-related eye diseases.
- The health functional food may be beverages, meat, chocolates, foods, snack, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplement foods.
- Hereinafter, the present invention will be described in more detail with embodiments. These embodiments are intended to more particularly illustrate the present invention, but the scope of the present invention is not limited to these embodiments.
- Preparation of Sargassum serratifolium Extract
- <1-1> Preparation of Sargassum serratifolium Ethanol Extract
- Sargassum serratifolium used in the present invention was collected by scuba diving, which grows naturally in Gijang-gun, Busan or Tongyeong-si, Gyeongsangnam-do, Korea. Professor Chang Kyun Choi of Department of Ecological Engineering, Pukyong National University confirmed the species of Sargassum serratifolium from Gijang-gun, and Professor Kim Namgil of Department of Marine Bioscience of Gyeongsang National University confirmed the species of Sargassum serratifolium from Tongyeong-si. Sargassum serratifolium was naturally dried in the shady and light spot and was ground. 2 kg of the powder obtained was added to 8 L ethanol (95% ethanol). The mixture was reflux-condensed to be extracted at 70° C. for 3 hours 3 times. The resultant was filtered with an ultrafilter (Nitto Denko, Japan). The ethanol was extracted from the filtrate at 40° C. in a vacuum rotary evaporator. Thus, 200±25 g of crude extract was obtained as an extracted residue. Thus, the obtained Sargassum serratifolium ethanol extract was used as a sample in the following experiment while being stored at 4° C. in a refrigerator.
- For reference, ultrafiltration is a process that may separate substances dissolved or dispersed in the liquid by particle size or molecular size, which separates particles in the middle region of microfiltration and reverse osmosis using pressure difference as a driving force. Ultrafiltration membranes have pore sizes in the range of about 10 Å to about 500 Å and are mainly used for the separation of saccharides, proteins, living body materials, and polymer substances with particle sizes of 1 nm to 0.1 μm. Its fundamental principle is the same as that of the microfiltration. However, the membrane structure of the microfiltration has a symmetric pore structure, but the ultrafiltration membrane has a dense layer structure of asymmetric structure so that the ultrafiltration can separate smaller particles compared with the microfiltration. In this experiment, ultrafiltration was carried out using a laboratory-scale Sehan ultrafiltration system (UF system, Sehan Tech, Korea). The Sehan ultrafiltration system was composed of a 20 L feed liquid tank, a feed liquid pump, a microfiltration cartridge, an ultrafiltration cartridge, and a pressure gauge for feed liquid and concentrate. Further, a hollow fiber membrane (MWCO=50 kDa) with an outer diameter of 50 mm, a length of 600 mm, and an area of 1 m2 was used. In the present invention, the ultrafiltration was carried out according to the continuous concentration mode. The sample solution was fed to the membrane module using a pump, which was performed at a flow rate of 0.1 L msec at 23° C. and a transmembrane pressure drop (TMP) of 0.2 bar to 2.0 bar. In this experiment, tube-type membranes with MWCO=50 kDa were used to have effects of removing even minute contaminants, bacterial debris, and viruses from the ethanol extract.
- <1-2> Preparation of n-Hexane Soluble Fraction from Sargassum serratifolium Ethanol Extract
- 50 g the Sargassum serratifolium ethanol extract prepared in Example 1-1 was dissolved in 1 L a mixed solvent of water and ethanol (9:1, v/v). The mixture was poured into a separatory funnel, and 1 L n-hexane having the same amount was added to the separatory funnel. Then, the separatory funnel was shaken, and they were equilibrated. Then, the upper portion of soluble n-hexane was collected, treated with sodium sulfate (anhydrous), filtered and concentrated. This procedure was repeated 5 more times to obtain 42 g n-hexane fraction.
- Each of the fractions obtained was used as a sample for the following experiments while being stored at 4° C. in a refrigerator.
- Separation of Sargahydroquinoic Acid, Sargachromenol, and Sargaquinoic Acid from Sargassum serratifolium Ethanol Extract
- <2-1> Separation of Sargahydroquinoic Acid
- 15 g the Sargassum serratifolium ethanol extract prepared in Example <1-1> was dissolved in 1 L a mixed solvent of water and ethanol (9:1, v/v), placed in a separatory funnel, and n-hexane having the same amount was added to the separatory funnel. After equilibration, the upper portion of soluble n-hexane was collected, dehydrated with anhydrous sodium sulfate, and then concentrated to separate a n-hexane fraction. 12.2 g the separated n-hexane fraction was dissolved in 120 mL methanol. The mixture was filtered through a membrane filter, and then 200 μL was injected so that they were separated in four fractions by HPLC with a Phenomenex C18 (2) (15 μm, 21.2 mm×250 mm) column (See
FIG. 1 ). A mixed solvent of methanol (A) and water (B) was used as the mobile phase of the chromatography, and the flow rate was set to 7 mL. The chromatography was set under a condition in which the column was washed at an initial concentration of A/B (90/10) to A/B (94/6) for 33 minutes, then A/B (94/6) to A/B (100/0) for 2 minutes, and A/B (100/0) for 10 minutes. Then, the column was equilibrated at a concentration of A/B (90:10) for 10 minutes. The chromatography was performed by automatic sample injection withAutosampler 50 to 100 times, thereby preparing the primary fraction of fraction No. 1 in a large amount. - The same instrument and column were used to increase the purity of the primary fraction obtained in large quantities. The chromatography was set under a condition in which the column was washed at an initial concentration of A/B (85/15) to A/B (87/13) for 26 minutes, then A/B (87/13) to A/B (100/0) for 2 minutes, and A/B (100/0) for 6 minutes. Then, the column was equilibrated at a concentration of A/B (87:13) for 10 minutes. The chromatography was performed by automatic sample injection with Autosampler, thereby preparing the secondary fraction of fraction No. 1 having a higher purity (See
FIG. 2 ). - No. 1 of the secondary fractions of fraction No. 1 was purified by re-chromatography (523 mg) under the same conditions and analyzed with an analytical column (Phenomenex C18 (2), 3 μm, 3 mm×150 mm). The results indicate that it was a single material. The separated product was analyzed by NMR and found to be sargahydroquinoic acid (hereinafter, referred to as “SHQ”) (See
FIG. 3 ). - <2-2> Separation of Sargachromenol
- The fraction No. 2 in
FIG. 1 was re-chromatographed using the same HPLC instrument and column as the fraction No. 1 in Example <2-1>. The chromatography was set under a condition in which the column was washed at an initial concentration of A/B (91.5/8.5) to A/B (92.2/7.8) for 26 minutes, then A/B (92.2/7.8) to A/B (100/0) for 2 minutes, and A/B (100/0) for 6 minutes. Then, the column was equilibrated at a concentration of A/B (91.5:8.5) for 10 minutes. The chromatography was performed by automatic sample injection withAutosampler 50 to 100 times, thereby preparing the secondary fraction of fraction No. 2 in a large amount (SeeFIG. 4 ). As illustrated inFIG. 4 , the fraction No. 2 showed three peaks. Among them, the peak No. 2 (Frc2-2) was re-purified to obtain a chromatogram as illustrated inFIG. 5 (126 mg). The separated product was analyzed by NMR and found to be sargachromenol (hereinafter, referred to as “SCA”) (SeeFIG. 5 ). - <2-3> Separation of Sargaquinoic Acid
- The fraction No. 3 in
FIG. 1 was re-chromatographed using the same HPLC instrument and column as the fraction No. 1 in Example <2-1>. The chromatography was set under a condition in which the column was washed at an initial concentration of A/B (93.4/6.6) to A/B (93.8./6.2) for 20 minutes, then A/B (93.8/6.2) to A/B (100/0) for 2 minutes, and A/B (100/0) for 6 minutes. Then, the column was equilibrated at a concentration of A/B (93.8:6.2) for 10 minutes. The chromatography was performed by automatic sample injection withAutosampler 50 to 100 times, thereby preparing the secondary fraction of fraction No. 3 in a large amount (SeeFIG. 6 ). As illustrated inFIG. 6 , the fraction No. 3 showed four peaks. Among them, the peak No. 4 (Frc3-4) was re-purified to obtain a chromatogram as illustrated inFIG. 7 (171 mg). The separated product was analyzed by NMR and found to be sargaquinoic acid (hereinafter, referred to as “SQA”) (SeeFIG. 7 ). - Evaluation of Cytotoxicity of Sargassum serratifolium Ethanol Extract and n-Hexane Fraction Thereof of the Present Invention
- RAW 264.7 cells (5×104 cells/well) were treated with the Sargassum serratifolium ethanol extract or hexane fraction thereof, respectively, of the present invention prepared in Example 1, and cultured in DMEM medium for 24 hours. 95 μL the medium and 5 μL the MTS solution were placed in a 96-well plate and were reacted for 3 hours. Then, the absorbance thereof was measured at 490 nm using a microplate reader. The experiments were repeated three times, and the mean value thereof was used as its measurement value.
- As illustrated in
FIG. 8 , the results indicate that the cytotoxicity of Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention to the macrophage line (RAW 264.7 cells) did not show up to a concentration of 8 μg/mL. - Antioxidative Activity of Sargassum serratifolium Ethanol Extract and n-Hexane Fraction Thereof of the Present Invention
- Nitric oxide, reactive oxygen species (ROS), antioxidative activity by DPPH method, ABTs antioxidative activity, and hydroxyl radical were measured so as to evaluate the antioxidative activity of Sargassum serratifolium ethanol extract and hexane fraction thereof of the present invention prepared in Example 1.
- <2-1> Measurement of Nitric Oxide
- RAW 264.7 cells (7×104 cells/well) were inoculated into 96-well plates using DMEM medium. New medium containing samples (Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1) and LPS (1 μg/mL) were co-treated and were cultured for 24 hours. The Griess reagent was used, so that the amount of NO produced was measured in the form of NO2− present in the cell culture medium. 100 μL the cell culture supernatant and 100 μL Griess reagent [1% sulfanilamide, 0.1% naphthyl ethylenediamine in 5% phosphoric acid] were mixed and reacted on a 96-well plate for 10 minutes. Then, the absorbance thereof was measured at 540 nm using an ELISA reader. Standard concentration curves were obtained by serial dilution of sodium nitrite (NaNO2).
- As illustrated in
FIG. 9 , the results show that the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with the Sargassum serratifolium ethanol extract and hexane fraction thereof in macrophages, respectively. The EC50 values of the ethanol extract and hexane fraction were 1.72 μg/mL and 1.51 μg/mL, respectively. - <2-2> Measurement of Intracellular Reactive Oxygen Species
- DCFH-DA was used to measure the amount of active oxygen so as to examine the inhibitory effect of Sargassum serratifolium extract on the production of reactive oxygen species (RAW 264.7 cells). Samples (Sargassum serratifolium ethanol extract or hexane fraction thereof of the present invention prepared in Example 1) and LPS (1 μg/mL) were co-treated and were cultured for 2 hours. Then, they were treated with 20 μM DCFH-DA and were cultured for 30 minutes. Thereafter, the cell culture supernatant was collected and measured by spectrofluorometry at an excitation wavelength of 485 nm and a radiation wavelength of 523 nm.
- As illustrated in
FIG. 10 , the results show that the production of reactive oxygen species induced by lipopolysaccharide (LPS) was decreased treatment-concentration dependently in the experimental group treated with the Sargassum serratifolium ethanol extract and hexane fraction thereof in macrophages, respectively. The IC50 values of the ethanol extract and hexane fraction were 0.92±0.09 μg/mL and 0.88±0.08 μg/mL, respectively. - <2-3> Measurement of Antioxidative Activity by DPPH Method
- The DPPH method (Blois, M. S.: Antioxidant determination by the use of a stable free radical, Nature, 26, 1199-1200, 1958) was used to measure the antioxidant effect of Sargassum serratifolium in vitro. The DPPH (1,1-diphenyl picrylhydrazyl) method is a method of measuring the antioxidative effect by hydrogen donating ability depending on the degree of discoloration of deep purple color by reduction due to a physiologically active substance having an antioxidative activity such as tocopherol, ascorbate, flavonoid compounds, aromatic amines, Maillard-type browning agent and peptide. For the measurement, 100 μl DPPH having a concentration of 200 μM and 100 μl the sample were mixed in a 96-well plate, and they reacted at room temperature for about 30 minutes. Then, the absorbance thereof was measured at 517 nm using a microplate reader. BHT was used as a positive control. The concentration thereof was compared to the same as that of the sample.
- DPPH radical scavenging activity was calculated by the method as described below.
-
Radical scavenging activity(%)=(A DPPH −A sample)/A DPPH×100 - As shown in Table 1, the results show that IC50 values of Sargassum serratifolium ethanol extract and hexane fraction thereof were 11.17±0.42 μg/mL and 9.05±0.21 μg/mL, respectively, and these values were lower than those of BHT used as a positive control (See Table 1).
- <2-4> ABTs Assay
- The ABTs assay is similar to the DPPH assay but differs in that antioxidative activity is measured by generating free radicals through chemical reactions. ABTs are reacted with potassium persulfate to generate ABTs anion radicals, which react with H-donors such as phenolic compounds to be converted to colorless ABTs. Accordingly, the degree of antioxidative activity may be determined by measuring the amount of ABTs consumed by reacting with a sample containing a phenolic compound.
- ABTs antioxidative activity was measured by partially modified Van den Berg (1999) and others using the discoloration of ABTs radical-specific green color by antioxidants.
- Potassium persulfate was added to 7 mM ABTS solution at a final concentration of 2.4 mM. They reacted in the dark for 12 hours to 16 hours at R/T so as to produce ABTs cations. The resulting ABTs cation was diluted to be used, having an absorbance value of 0.7±0.02. 10 μL of the sample was treated with 190 μL ABTs+ working solution and reacted for 6 minutes in a 96-well plate. The absorbance thereof was measured at 732 nm. The radical scavenging activity was calculated from the measured values as follows. BHT was used as a positive control. The antioxidant ability of the sample is determined by the IC50 value in which 50% of ABTs was reduced.
-
Percentage inhibiting activity I(%)=(A control A sample)/A control/×100 - Acontrol: Control (blank sample)
- Acontrol: Sample measurement value
- As shown in Table 1, the results show that IC50 values of Sargassum serratifolium ethanol extract and hexane fraction thereof were 17.44±3.1 μg/mL and 14.69±3.4 μg/mL, respectively, and these values were somewhat higher than those of BHT used as a positive control (See Table 1).
- <2-5> Hydroxyl Radical Scavenging
- Hydroxyl radicals (—OH) are the most reactive radicals among oxygen radicals, which occur during aerobic metabolism in the human body. These radicals damage peripheral cells to create collateral living body molecules. A deoxyribose test was performed so as to measure the ability to scavenge hydroxyl radicals. Hydroxyl radicals attack deoxyribose to create small fragments. Some of which are pink when added with TBA (thiobarbituric acid) under an acidic pH environment, so the degree of damage by hydroxyl radicals is measured by absorbance at 532 nm.
- Experimental methods described in Chandini, Ganesan, and Bhaskar (Chandini, S. K., Ganesan, p., and Bhaskar, N. (2008) In vitro antioxidant activities of three selected brown seaweeds of India. Food Chemistry, 107, 707-713) were modified to be used. This reaction used 20 mM phosphate buffer (pH 7.4). Ferric chloride (FeCl3) and EDTA (ethylenediaminetetraacetic acid), respectively, were dissolved as to be 1 mM, and deoxyribose, a reaction substrate, was added to be 2.8 mM, thereby preparing a working solution. 1 ml the sample to be measured was mixed with the working solution, and 0.1 ml ascorbic acid (1 mM) is added to form Fe2+-EDTA mixture which is an oxidized form of ferric chloride (FeCl3) and ethylenediamine tetraacetic acid (EDTA). Then, 0.5 ml of 20 mM hydrogen peroxide (H2O2) was added to form Fe3+-EDTA and HO radical. They were then incubated at 37° C. for 1 hour. After the incubation, 1 ml of 2.8% Trichloroacetic acid (TCA) and 1% TBA, respectively, were added. The mixture was boiled in boiling water at 100° C. for 30 minutes. The absorbance thereof was measured. BHT (2 μg/ml to 25 μg/ml) was used as a positive control.
-
Hydroxyl radical scavenging ability(%)=(A control −A sample)/A control×100 - Acontrol: Control (blank sample)
- Acontrol: Sample measurement value
- As shown in Table 1, the results show that IC50 values of Sargassum serratifolium ethanol extract and hexane fraction thereof were 1.12±0.15 μg/mL and 1.08±0.19 μg/mL, respectively. These values indicate that the antioxidative activity thereof was showed at a lower concentration compared to BHT used as a positive control (See Table 1).
-
TABLE 1 Antioxidant activity of Sargassum serratifolium ethanol extract and hexane fraction thereof DPPH ABTs OH radical (IC50, μg/ml) (IC50, μg/ml) (IC50, μg/ml) Sargassum serratifolium 11.17 ± 0.42 17.44 ± 3.1 1.12 ± 0.15 Hexane fraction of 9.05 ± 0.21 14.69 ± 3.4 1.08 ± 0.19 Sargassum serratifolium BHT (Control) 11.18 ± 0.15 7.77 ± 0.74 1.675 ± 0.21 - Evaluation of Cytotoxicity of Sargassum serratifolium Ethanol Extract and Compounds Separated Therefrom (Sargahydroquinoic Acid (SHO), Sargachromenol (SCM), and Sargaquinoic Acid (SOA)) of the Present Invention on 661W Photoreceptor Cells
- In this experiment, the cytotoxicity of Sargassum serratifolium ethanol extract and the compounds separated therefrom prepared in Examples 1 and 2 to 661W photoreceptor cells was confirmed. The 661W photoreceptor cells are cell lines established by Dr. Al-Ubaidi. Dr. Al-Ubaidi supplied the cells, which were used in the experiment.
- 661W photoreceptor cells were cultured in 96-wells at a concentration of 3×103 cells/well. Then, they were treated with 1.0 μg/ml Sargassum serratifolium ethanol extract or compounds separated therefrom (sargahydroquinoic acid (SHQ), sargachromenol (SCM), and sargaquinoic acid (SQA)) at a concentration of 1.0 μM and cultured for 24 hours. Then, the medium was replaced with medium containing MTS reagent. Then, they were cultured for 1 hour. Cell viability was measured by measuring the absorbance at 490 nm and comparing the results. The cell viability was analyzed by Celltiter96 Aqueous One solution assay kit (Promega).
- As illustrated in
FIGS. 11 and 12 , the results indicate that no cytotoxicity was observed in the 661W photoreceptor cells in both Sargassum serratifolium ethanol extract (1 μg/ml) and the compound separated therefrom (1 μM). For reference, there was no cytotoxicity of Sargassum serratifolium ethanol extract up to a concentration of 2 μg/ml. There were also no cytotoxicity of sargahydroquinoic acid up to a concentration of 2.5 μM, sargachromenol up to a concentration of 2.5 μM, and sargaquinoic acid up to a concentration of 1.0 μM. - Protective Effect of Sargassum serratifolium Ethanol Extract and Compounds Separated Therefrom (Sargahydroquinoic Acid (SHO), Sargachromenol (SCM), and Sargaquinoic Acid (SOA)) of the Present Invention on 661W Photoreceptor Cells from Oxidative Stress
- <4-1> Effect on the Cell Viability of 661W Cells Under Oxidative Stress
- In order to examine the protective effect of the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention prepared in Examples 1 and 2 on 661W photoreceptor cells, it is examined how the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention effect on the death of 661W photoreceptor cells treated with atRAL.
- In other words, the atRAL is an intermediate metabolite of the visual cycle and is an aldehyde-type compound. The atRAL may induce excessive oxidative stress in cells. Therefore, when 661W photoreceptor cells were treated with the atRAL compound to induce the oxidative stress, the protective effect of the Sargassum serratifolium ethanol extract and the compound separated therefrom of the present invention on 661W photoreceptor cells was examined.
- In detail, 661W photoreceptor cells were cultured in 96-wells at a concentration of 3×103 cells/well and treated with atRAL having a concentration of 1.8 μM (Sigma Aldrich, St. Louis, Mo., USA) for 24 hours. Then, the medium was replaced with medium containing MTS reagent, and they were cultured for 1 hour. The absorbance thereof was measured at 490 nm, and the results were compared to determine cell viability. The cell viability thereof was measured by Celltiter96 Aqueous One solution assay kit (Promega).
- As illustrated in
FIG. 13 , the results indicate that the cell viability of 661W photoreceptor cells was reduced by about 55% in the only atRAL-treated group, whereas the cell viability in the experimental group treated with 0.5 μg/mL of Sargassum serratifolium ethanol extract and atRAL was increased by about 25% compared to the experimental group treated with the only atRAL. - Further, the cell viability of 661W photoreceptor cells was more than 90% in the experimental group treated with 0.5 μM sargahydroquinoic acid (SHQ), sargachromenol (SCM), and sargaquinoic acid (SQA), respectively, so that no significant difference was found between the atRAL-treated group and the untreated group. The results demonstrate that the compounds derived from Sargassum serratifolium of the present invention have a very high protection effect on 661W photoreceptor cells.
- In sum, it was concluded that the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention had the effect of protecting the photoreceptor cells within the range of showing no cytotoxicity.
- <4-2> Inhibitory Effect on Reactive Oxygen Species in 661W Cells Under Oxidative Stress
- In order to check whether Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention prepared in Examples 1 and 2 have the antioxidant activity in 661W photoreceptor cells under oxidative stress, the inhibitory effect of the reactive oxygen species in 661W photoreceptor cells treated with atRAL was observed in this experiment.
- For reference, 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) converts to DCF, which expresses fluorescence in response to oxidative stress in cells. Therefore, the expression of DCF in cells is used as an indicator of the degree of oxidative stress.
- In order to examine the antioxidative effect of the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention, atRAL (1.8 μM) and Sargassum serratifolium ethanol extract (0.5 μg/mL), sargachromenol (0.5 μM), sargahydroquinoic acid (0.5 μM) or sargaquinoic acid (1.0 μM) were added to medium mixed with DCFH-DA (20 μM), and the photoreceptor cells were treated with them and cultured for 30 minutes. Then, the cells were washed with PBS, and the cells were recovered. The cells expressing the fluorescence were measured using flow cytometry.
- As illustrated in
FIG. 14 , the results demonstrate that the cells treated with atRAL only had a fluorescence expression level having about 80% higher than that of the control group. In the group treated with atRAL and Sargassum serratifolium ethanol extract (0.5 μg/mL), the fluorescence expression level was reduced by about 75% compared to the group treated with atRAL only. In the groups treated with atRAL and sargachromenol (0.5 μM), sargahydroquinoic acid (0.5 μM) or sargaquinoic acid (1.0 μM), the fluorescence expression levels were reduced by 76%, 77%, and 73%, respectively, and there was no difference from the control group untreated with atRAL. - Therefore, the Sargassum serratifolium ethanol extract and compound separated therefrom were found to effectively inhibit atRAL-induced oxidative stress, thereby protecting photoreceptors.
- <4-3> Inhibitory Effect on Malondialdehyde in 661W Cells Under Oxidative Stress
- In order to check whether the Sargassum serratifolium ethanol extract and the compounds separated therefrom of the present invention prepared in Examples 1 and 2 have antioxidant activity in 661W photoreceptor cells under oxidative stress, the inhibitory level of malondialdehyde (MDA) production in 661W photoreceptor cells treated with atRAL was observed in this experiment. For reference, the malondialdehyde (MDA) is the result of lipid peroxidation by excessive oxidative stress in cells, and thus the amount of MDA in cells is a factor to measure the degree of oxidative stress.
- In detail, samples of each of Sargassum serratifolium ethanol extract and the compounds separated therefrom were mixed with a specific amount of atRAL (1.8 μM) and Sargassum serratifolium ethanol extract (0.5 μg/mL), sargachromenol (0.5 μM), sargahydroquinoic acid (0.5 μM) or sargaquinoic acid (1.0 μM). The photoreceptor cells were treated with mixtures. Then, they were cultured for 2 hours. The cells were then washed with PBS and the intracellular proteins were recovered. The number of proteins denatured by the lipid peroxides in cells was analyzed by protein immunoassay using MDA immunoblot kit (Cell biolabs).
- As illustrated in
FIG. 15 , the results indicate that the cells treated with atRAL only showed an increase in expression level of protein denatured by MDA compared with the control, whereas the group treated with atRAL and Sargassum serratifolium ethanol extract having 0.5 μg/mL of the present invention has decreased expression level of MDA peroxidase protein compared with the group treated with atRAL only. The expression level of MDA peroxidase protein was similarly decreased in the experimental groups treated with atRAL and compounds separated from Sargassum serratifolium ethanol extract, respectively. - Therefore, it is determined that the Sargassum serratifolium ethanol extract and compound separated therefrom effectively inhibit atRAL-induced oxidative stress so that the photoreceptors are protected by inhibiting peroxidation of cell membrane lipid component.
- Production of Functional Cosmetic Composition with Antioxidative Activity of the Present Invention
- <1-1> Toner (Skin)
- The toner (skin) containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
-
TABLE 2 Example of toner formulation of the present invention Composition Content(weight %) Sargassum serratifolium ethanol 1 to 3 extract or hexane fraction Glycerin 5.0 1,3-Butylene glycol 3.0 REG 1500 1.0 Allantoin 0.1 DL-Panthenol 0.3 EDTA-2Na 0.02 Benzophenone-9 0.04 Sodium hyaluronate 5.0 Ethanol 10.0 Octyldodeceth-16 0.2 Polysorbate 20 0.2 Unicide-U13 0.01 Flavor Trace Distilled water Residue Total 100 - <1-2> Toner (Lotion)
- The toner (lotion) containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
-
TABLE 3 Example of toner formulation of the present invention Composition Content(weight %) Sargassum serratifolium ethanol 1 to 3 extract or hexane fraction Glyceryl stearate SE 1.5 Cetearyl alcohol 1.5 Lanolin 1.5 Polysorbate 60 1.3 Sorbitan stearate 0.5 Hardened vegetable oil 4.0 Mineral oil 5.0 Trioctanoin 2.0 Dimethicone 0.8 Tocopherol acetate 0.5 Carboxyvinyl polymer 0.12 Glycerin 5.0 1,3-Butylene glycol 3.0 Sodium hyaluronate 5.0 Triethanolamine 0.12 Unicide-U 13 0.02 Flavor Trace Distilled water Residue Total 100 - <1-3> Nourishing Cream
- The nourishing cream containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
-
TABLE 4 Example of nourishing cream formulation of the present invention Composition Content(weight %) Sargassum serratifolium ethanol 1 to 10 extract or hexane fraction Lipophilic monostearic acid glycerin 1.5 Cetearyl alcohol 1.5 Stearic acid 1.0 Polysorbate 60 1.5 Sorbitan Stearate 0.6 Isostearyl isostearate 5.0 Squalene 5.0 Mineral oil 35.0 Dimethicone 0.5 Hydroxyethyl cellulose 0.12 Glycerin 6.0 Triethanolamine 0.7 Unicide-U13 0.02 Flavor Trace Distilled water Residue Total 100 - <1-4> Massage Cream
- The massage cream containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
-
TABLE 5 Example of massage cream formulation of the present invention Composition Content(weight %) Sargassum serratifolium ethanol 1 to 3 extract or hexane fraction Propylene glycol 6 Glycerin 4.0 Triethanolamine 0.5 Wax 2.0 Tocopheryl acetate 0.1 Polysorbate 60 3.0 Sorbitan sesquioleate 2.5 Cetearyl alcohol 2.0 Liquid paraffin 30.0 Carboxyvinyl polymer 0.5 Flavor Trace Distilled water Residue Total 100 - <1-5> Pack
- The pack containing the Sargassum serratifolium ethanol extract or hexane fraction of the present invention was produced in the following composition ratio using a conventional method.
-
TABLE 6 Example of pack formulation of the present invention Composition Content(weight %) Sargassum serratifolium ethanol 1 to 3 extract or hexane fraction Glycerin 10.0 Betaine 5.0 REG 1500 2.0 Allantoin 0.1 DL-panthenol 0.3 EDTA-2Na 0.02 Benzophenone-9 0.04 Hydroxyethylcellulose 0.1 Sodium hyaluronate 80. Carboxyvinyl polymer 0.2 Triethanolamine 0.18 Octyldodecanol 0.3 Octyldodeceth-16 0.4 Ethanol 6.0 Unicide-U13 0.01 Flavor Trace Distilled water Residue Total 100 - As described above, the present invention has been described to focus on the preferred embodiments. Those of ordinary skill in the art to which the present invention belongs may understand that the present invention may be carried out in various forms without departing from the essential scope of the present invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a limited purpose. The scope of the present invention is set forth in the following claims, rather than the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (20)
1. A composition having an antioxidative activity, the composition comprising a Sargassum serratifolium extract or a fraction thereof as an active ingredient.
2. The composition of claim 1 , wherein the extract is extracted with at least one solvent selected from the group consisting of lower alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, water, and hexane.
3. The composition of claim 2 , wherein the lower alcohols having 1 to 4 carbon atoms include ethanol.
4. The composition of claim 1 , wherein the fraction is a hexane fraction of the Sargassum serratifolium extract.
5. The composition of claim 1 , comprising the Sargassum serratifolium extract or the fraction thereof in a concentration of 0.1 μg/ml to 1000 μg/ml.
6. The composition of claim 1 , wherein the composition is a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition.
7. A method of treating skin from aging effects of reactive oxygen species (ROS) on a subject comprising topically administering the composition of claim 1 to the subject in need thereof.
8. The method of claim 7 , wherein the extract is extracted with an ethanol solvent.
9. The method of claim 7 , wherein the fraction is a hexane fraction of the Sargassum serratifolium extract.
10. The method of claim 7 , wherein the composition is a cosmetic composition having a formulation selected from the group consisting of a toner, a gel, soluble liquid, a milky lotion, a nutrition cream, a massage cream, an essence, an oil-in-water type emulsion, a water-in-oil type emulsion, a paste-like anhydrous product, a solid anhydrous product, an oil dispersion in aqueous phase using small spheres, an ionic lipid vesicle, a nonionic lipid vesicle, ointment, cleansing foam, cleansing water, pack, body oil, oil-in-water type makeup base, water-in-oil type makeup base, foundation, skin cover, lipstick, lip gloss, face powder, twin cake, eyeshadow, mascara, cheek color, and eyebrow pencil.
11. A method of treating eye disease, comprising administering to a person in need thereof, a pharmaceutical composition comprising a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
12. The pharmaceutical composition of claim 11 , wherein the extract is extracted with an ethanol solvent.
13. The pharmaceutical composition of claim 11 , wherein the compound is sargahydroquinoic acid, sargaquinoic acid, or sagachromenol.
14. The pharmaceutical composition of claim 11 , wherein the eye disease is one selected from the group consisting of age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, choroidal neovascular membrane, uveitis, myopic degeneration, ocular tumor, central retinal vein occlusion, skin flushing, ocular neovascularization, central serous retinopathy, dry eye syndrome, central retinal artery occlusion, and cystoid macular edema.
15. The method of claim 11 , wherein the composition is a food composition.
16. The method of claim 15 , wherein the extract is the Sargassum serratifolium ethanol extract, and
wherein the compound is sargahydroquinoic acid, sargaquinoic acid, or sagachromenol.
17. A health functional food for preventing or alleviating an eye disease, the health functional food comprising a Sargassum serratifolium extract or a compound separated therefrom as an active ingredient.
18. The health functional food of claim 17 , wherein the extract is the Sargassum serratifolium ethanol extract, and
wherein the compound is sargahydroquinoic acid, sargaquinoic acid, or sagachromenol.
19. The health functional food of claim 17 , wherein the food is one selected from the group consisting of a beverage, meat, chocolate, a food, snack, pizza, ramen, another noodle, a gum, candy, ice cream, an alcoholic beverage, a vitamin complex, and a health supplement food.
20. The health functional food of claim 17 , wherein the Sargassum serratifolium extract or the compound separated therefrom has an effect of protecting a photoreceptor cell by antioxidative activity.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0182907 | 2015-12-21 | ||
KR1020150182907A KR101893250B1 (en) | 2015-12-21 | 2015-12-21 | An antioxidant composition comprising the extract or fraction of Sargassum serratifolium |
PCT/KR2016/003975 WO2017111211A1 (en) | 2015-12-21 | 2016-04-18 | Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/003975 A-371-Of-International WO2017111211A1 (en) | 2015-12-21 | 2016-04-18 | Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/036,456 Division US11590185B2 (en) | 2015-12-21 | 2020-09-29 | Antioxidant composition comprising Sargassum serratifolium extract or fraction thereof as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190142885A1 true US20190142885A1 (en) | 2019-05-16 |
Family
ID=59090647
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/078,401 Abandoned US20190142885A1 (en) | 2015-12-21 | 2016-04-18 | Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient |
US17/036,456 Active 2037-01-24 US11590185B2 (en) | 2015-12-21 | 2020-09-29 | Antioxidant composition comprising Sargassum serratifolium extract or fraction thereof as active ingredient |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/036,456 Active 2037-01-24 US11590185B2 (en) | 2015-12-21 | 2020-09-29 | Antioxidant composition comprising Sargassum serratifolium extract or fraction thereof as active ingredient |
Country Status (3)
Country | Link |
---|---|
US (2) | US20190142885A1 (en) |
KR (1) | KR101893250B1 (en) |
WO (1) | WO2017111211A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344345A (en) * | 2022-01-10 | 2022-04-15 | 中国科学院南海海洋研究所 | Seaweed extract capable of effectively relieving skin sunburn and preparation method and application thereof |
WO2023122288A3 (en) * | 2021-12-23 | 2023-08-31 | C-Combinator, A Public Benefit Corporation | Methods for extracting alginate biomass and related compositions |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102157413B1 (en) * | 2017-12-08 | 2020-09-17 | 부경대학교 산학협력단 | Composition for preventing and treating liver diseases comprising extract of sargassum serratifolium |
KR101998511B1 (en) * | 2018-01-29 | 2019-07-09 | 동의대학교 산학협력단 | Composition containing extract of Sargassum serratifolium for preventing or treatmenting of osteoporosis |
KR102123565B1 (en) * | 2019-02-12 | 2020-06-16 | 제주대학교 산학협력단 | A composition comprising seaweed extracts or fraction having anti-oxidation or anti-inflammation activity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5165933A (en) * | 1989-02-10 | 1992-11-24 | Kabushikikaisha Kibun | Restriction enzyme inhibitor |
KR101035858B1 (en) * | 2009-07-14 | 2011-05-19 | 한불화장품주식회사 | Sargassum sp. extract that have low photo-induced cytotoxicity, preparation method thereof and cosmetic composition containing the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101110064B1 (en) * | 2009-06-08 | 2012-03-14 | 재단법인 제주테크노파크 | Anti-inflammatory Composition |
KR101839013B1 (en) | 2010-11-25 | 2018-03-15 | (주)아모레퍼시픽 | Cosmetic composition containing SARGASSUM FULVELLUM extract, CODIUM FRAGILE extract and UNDARIA PINNATIFIDA extract |
KR101302739B1 (en) * | 2010-12-28 | 2013-10-08 | 재단법인 제주테크노파크 | Composition for Improving Allergy Disease Using an Extract of Sargassum muticum or the Effective Compound Isolated from the Extract |
KR101938891B1 (en) * | 2012-06-19 | 2019-01-15 | 부경대학교 산학협력단 | Photoaging Protective Composition Containing Chromenes from Sargassum horneri |
KR101589002B1 (en) * | 2015-07-31 | 2016-01-28 | 부경대학교 산학협력단 | Cosmetic composition containing sargassum serratifolium extract for improving skin wrinkle |
-
2015
- 2015-12-21 KR KR1020150182907A patent/KR101893250B1/en active IP Right Grant
-
2016
- 2016-04-18 US US16/078,401 patent/US20190142885A1/en not_active Abandoned
- 2016-04-18 WO PCT/KR2016/003975 patent/WO2017111211A1/en active Application Filing
-
2020
- 2020-09-29 US US17/036,456 patent/US11590185B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5165933A (en) * | 1989-02-10 | 1992-11-24 | Kabushikikaisha Kibun | Restriction enzyme inhibitor |
KR101035858B1 (en) * | 2009-07-14 | 2011-05-19 | 한불화장품주식회사 | Sargassum sp. extract that have low photo-induced cytotoxicity, preparation method thereof and cosmetic composition containing the same |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023122288A3 (en) * | 2021-12-23 | 2023-08-31 | C-Combinator, A Public Benefit Corporation | Methods for extracting alginate biomass and related compositions |
CN114344345A (en) * | 2022-01-10 | 2022-04-15 | 中国科学院南海海洋研究所 | Seaweed extract capable of effectively relieving skin sunburn and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2017111211A1 (en) | 2017-06-29 |
US11590185B2 (en) | 2023-02-28 |
KR101893250B1 (en) | 2018-10-04 |
US20210060104A1 (en) | 2021-03-04 |
KR20170073987A (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11590185B2 (en) | Antioxidant composition comprising Sargassum serratifolium extract or fraction thereof as active ingredient | |
CN101346136A (en) | Protection of oxidizable agents | |
KR20070069204A (en) | Abnormal protein removing composition | |
KR101787074B1 (en) | Cosmetic compositions comprising mixed extracts of natural products for skin-whitening and improving skin-wrinkle | |
KR101026879B1 (en) | Producing method of cosmetic composition for improving skin wrinkle | |
KR101467627B1 (en) | UV-induced Apoptosis in human Keratinocytes Suppressing Composition Containing Extract of Undaria crenata | |
KR101796866B1 (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising at least one selected from the group consisting of cymene, behenic acid, 2-methoxynaphthalene, thymol and salts thereof | |
WO2009141543A1 (en) | Use of a berry extract, especially a wolfberry extract, as an anti-pollutant | |
JP2016196429A (en) | Nrf2 ACTIVATOR | |
JP2008031123A (en) | Liver-protecting agent | |
KR101721022B1 (en) | Composition for comprising adipic acid for improving skin wrinkle or enhancing skin elasticity | |
KR101718190B1 (en) | Composition for protecting or curing human keratinocyte against UVB containing Extract of Carpomitra costata Stackhouse Batters as an active ingredient | |
KR101286140B1 (en) | Cosmetic composition for moisturizing and anti-irritation of skin containing polysaccharide from nelumbo nucifera rhizome | |
JP2006089385A (en) | Composition for beautiful skin | |
KR20220150943A (en) | Oat extract or composition comprising avenanthramide and β-glucan | |
KR20160061601A (en) | Cosmetic composition and pharmaceutical composition containing the extract of Corchorus olitorius L, ginko and chlorella | |
KR100930592B1 (en) | Skin whitening and antioxidant composition containing extracts against | |
KR101597505B1 (en) | Cosmetic composition for prevention or improvement of sensitive skin comprising mixture oil extracted of Euryale ferox, Euphorbia lathyris L. and Rosa multiflora fruit | |
KR101461704B1 (en) | Composition for protecting skin and inhibiting damage of skin against UV Comprising Polysiphonia morrowii Harvey | |
KR102646357B1 (en) | Tannin-containing plant extract-derived extracellular vesicles and use thereof for improving skin conditions | |
KR101448351B1 (en) | UV-induced Apoptosis in Human Keratinocytes Suppressing Composition Containing Extract of Polyopes affinis | |
KR102051581B1 (en) | Cosmetic Composition For Skin Improvement Comprising Freekeh Extracts And Fractions As Active Component | |
KR20230068334A (en) | Composition for preventing and treating of atopic dermatitis comprising Luteolin glycoside as an active ingredient | |
KR101702493B1 (en) | Composition for comprising borneol for moisturizing and improving skin wrinkle | |
KR20230055778A (en) | Composition for antioxidation, whitening or wrinkle improvement comprising Actinidia arguta extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY CO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, HYEUNG-RAK;LIM, SU-JIN;KWON, MI-SUNG;AND OTHERS;SIGNING DATES FROM 20180725 TO 20180726;REEL/FRAME:048280/0069 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |